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Airway reactivity in seafood industry workers  
 
Workers in the Norwegian salmon industry show enhanced occurrence of respiratory symptoms from 
both the upper and lower parts of the airways 2, 3. Frequent sneezing, running nose, sore throat, cough 
with phlegm, wheezing, and shortness of breath are all symptoms that are found to display increased 
frequency in salmon workers compared to control groups. Although the prevalence of asthma 
symptoms is quite high, atopic status are not found to be associated with asthma in the salmon 
workers. None of the examined workers in the study conducted by Bang and co-workers (2005)2 had 
specific IgE towards salmon antigen, and only 2,2% of salmon workers displayed IgE towards salmon 
in the follow up study by Shiryaeva and co-workers (2010)3. 
 
The upper airways are a portal of entry for workplace-related hazardous material into the respiratory 
system. Allergens, irritants, and carcinogens can all cause occupational diseases of the airways 4. A 
variety of occupational irritant exposures can be associated with airway symptoms, including inhalation 
of biological agents. Previous research has shown that production workers in the fish industry inhale 
aerosols containing biological material (bio-areosols) 2, 5. The biological material may originate from 
the raw material itself or from microbiological organisms like bacteria and molds in the environment. 
Inhalation of particulate matter may affect the airway epithelial cells, and surface epithelium in the 
upper and lower parts of the respiratory tract can contribute to an inflammation response by production 
and secretion of cytokines.  
 
Occupational reactions to seafood can manifest as rhinitis, conjunctivitis, asthma, urticaria, protein 
contact dermatitis, and occasionally systemic anaphylactic reactions 6. Processing of clam, shrimp, 
and crab is associated with increased risk of occupational asthma, but in a majority of the cases it is 
not established whether the asthma is of allergic or non-allergic origin 2, 6-11. Occupational exposure to 
bony fish (salmon) is also linked to occupational asthma, but the prevalence of diagnosed 
occupational asthma is lower (2 – 8%) compared to shellfish exposure (4 – 36%) 6, 12, 13. 
The observed airway symptoms in fish industry workers may be due to non-allergic inflammatory 
processes caused by inhalation of biological components in the working environment (endotoxins, 
moulds, proteases) 2. Concomitant exposures to agents like histamine, endotoxin and mycotoxins in 
organic dust and bio aerosols have been known to cause mucous membrane irritation and/or asthma 
on an inflammatory basis 6, 7, 11. In the household waste recycling industry, bio-aerosols containing 
microbial components (endotoxin and β(1-3)-glucans) are shown to induce changes consistent with 
non-allergic inflammation of both the upper and lower airways, while fungal spores are shown to 
impact on non-allergic upper airway inflammation 14, 15. Additionally, there are workplace factors of 
non-biological origin that also might trigger non-allergic respiratory symptoms of asthma, namely 
physical factors (hypertonic saline aerosols, cold air, steam vapors) or chemicals (formaldehyde used 
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in fishmeal production, sulphite preservatives, amines and other anti-microbial agents used to soak 
gloves, forklift exhaust emissions) 2, 16-18.  
As opposed to Tarlo and Liss (2003) reporting more than 90% of occupational asthma cases to be of 
immunologic origin, Douwes and co-workers (2002) estimate that, based on a systematic review of 
population based studies, at most, only 50% of asthma cases in the referred populations are 
attributable to eosinophilic allergic airway inflammation 19, 20. These latter numbers are also supported 
by more recent literature 21, 22 and suggests a possible role of neutrophil-mediated asthma triggered by 
endotoxins and other non-specific irritant factors in causing asthma symptoms 19.  
 
Symptoms occurring from the airways may be indicative of various airway diseases, but in the work 
related to seafood industry focus is mainly on rhinitis and asthma. Rhinitis is defined as inflammation 
of the nasal mucosa and is characterized by rhinorrhea, sneezing, nasal congestion and/or nasal 
pruritus 23, 24. Allergic rhinitis, a subset of rhinitis, is induced by sensitization to allergens with resultant 
production of allergen-specific IgE. The condition was in 2005 reported to be the most frequent and 
troublesome allergic disorder in westernized countries 25. Non-allergic rhinitis (irritant induced) can be 
secondary to a variety of causes (amongst others inflammation, drug-induced, disease-related) and is 
mediated by non-IgE-dependent mechanisms. Asthma is a lung disease characterized by variable 
airflow obstruction (which is typically reversible), cellular inflammation, and/or airway 
hyperresponsiveness. The etiology of asthma may be immunologic where the process is induced by 
an IgE mechanism or other immune responses such as cell-mediated immunity to specific agents, but 
it may also be irritant-induced involving non-immunological mechanisms of inflammation. These 
diseases are termed occupational rhinitis (OR) and occupational asthma (OA) when the initiation and 
progression of the disease is due to causes and conditions attributable to a particular work 
environment and not to stimuli encountered outside the workplace 26-29. Rhinitis and asthma are often 
associated and share similar immunopathological features, and the documentation of how upper 
airway disease impacts on the lower airways are increasing 24.  
 
Allergic diseases associated with occupational exposure to crab is quite well characterized 6; however, 
earlier researches contain few clear correlations between airway symptoms and enhanced levels of 
specific immunoglobulins against fish. In most studies regarding occupational exposure to fish the 
occurrence of symptoms exceeds the occurrence of diagnosed allergic disease.  
The fact that the prevalence of work-related airway symptoms is much higher than diagnosed allergic 
disease due to fish might suggest that not all symptoms experienced by workers can be attributable to 
fish allergens aerosolized in the working environment. Other allergens such as Anisakis simplex (fish 
parasite) could possibly be important in causing occupational allergic IgE-mediated sensitization and 
respiratory allergy 30-32, but the observed symptoms could also be caused by non-allergic mechanisms. 
 
Protein-cleaving enzymatic activity by proteases is shown to be important for the induction of cytokine 
production following exposure to molds 33, 34, mites 35, 36, cockroaches 37, and bacteria 38-41. The study 
from Bang and co-workers (2005) has shown that workers in the fish industry might inhale aerosols 
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containing biologic material that can act as irritants 2. Additionally, unpublished data from our 
laboratory show protein-cleaving enzymatic activity in storage water and fish juice sampled from work 
benches, with the highest activity of trypsin. Protease activity is also found in air samples taken from 
the breathing zone of the industry workers. Recently, trypsin is shown to be capable of contributing to 
airway inflammation 42, 43 and asthma 44. The discovery of the protease-activated receptors (PARs) 45, 
46 has lead to an increased understanding of the mechanisms by which trypsin and other proteases 
may trigger cellular effects in the airways.  
 
 
Serine proteases  
 
Proteases are traditionally regarded as digestive protein-degrading enzymes but are now gaining 
recognition as multifunctional hormone-like signalling molecules that are implicated in a vast number 
of physiological and pathophysiological events 47. Proteases can regulate cellular signalling events 
through their interaction with a large variety of targets, including pro-hormones, kininogens, 
chemokines precursors, proteinase zymogens, and various receptors including the PAR family.  
Proteases may be divided into five different classes based on their mechanism of catalysis; aspartate, 
metallo-, cysteine, serine and threonine proteases. The aspartate and metalloproteases use an 
activated water molecule as a nuclephile to attack peptide bonds, while a catalytic amino acid residue 
in the active site of the protease serves as the nucleophile for the remaining proteases. Approximately 
550 genes encode proteases in the human genome, with the metalloproteases and serine proteases 
making up the bulk of these 48. More than one third of all known proteolytic enzymes are serine 
proteases grouped into 13 clans and 40 families 49. The family name stems from the nucleophilic 
serine (Ser) in the enzyme active site, which attacks the carbonyl moiety of the substrate peptide bond 
to form an acyl-enzyme intermediate 50. Nucleophilicity of the catalytic Ser is typically dependent on a 
catalytic triad of aspartic acid (Asp), histidine (His), and Ser residues, commonly referred to as the 
charge relay system 51. Serine proteases are widely distributed in nature and found in all kingdoms of 
cellular life as well as many viral genomes. They are usually endopeptidases and catalyze bonds in 
the middle of a polypeptide chain. However, several families of exoproteases have been described 
that remove one or more amino acid from the termini of target polypeptide chains. The clan PA 
proteases bearing the trypsin fold are the largest family of serine proteases and perhaps the best 
studied group of enzymes. Digestive enzymes such as trypsin cleave polypeptide chains at positively 
charged (arginine/lysine) residues 52. A number of key biological processes rely on clan PA proteases 
and chiefs among them are blood coagulation and the immune response. Besides eliciting a number 
of physiological processes, endogenous or exogenous proteases in excessive amounts may result in a 
shift from the normal physiological situation to pathological conditions. The end result of 
disproportionate protease activity in the airways closely resembles the pathophysiology of rhinitis and 
asthma and includes the following events listed by Reed (2007) 53;  
 
1) Disruption of tight junctions and desquamation of epithelial cells 34. 
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2) Chemokine and eotaxin production and release from macrophages and epithelial cells 
recruit neutrophils and eosinophils 54. 
3) Increased bronchial smooth muscle contraction 55, 56. 
4) Increased mitogenesis of smooth muscle and fibroblasts, augmented collagen production 
and promotion of angiogenesis contribute to airway remodelling 57-59.  
5) Exogenous proteases from mites and molds augment the IgE response to bystander 
antigens 60-62. The intercellular signalling involved in this switch to a Th2 response has not 
been fully elucidated. 
 
In addition to effects observed in the airways, proteases are found to affect the vascular, renal, 
gastrointestinal, musculoskeletal, and nervous systems, and can promote cancer metastasis and 
invasion. Proteases must now be considered as important “hormonal” regulators of inflammation, 
nociception and cardiovascular function and many physiological responses mediated by serine 
proteases can occur through the PAR family. An outline of the PAR family and a more detailed 
description of PAR2 mediated activation and signalling is given in the below sections. 
 
 
Protease activated receptor (PAR) family 
 
The protease-activated receptors (PARs) belong to family 1 of the G protein-coupled superfamily of 
receptors, branching off from relatedness to the neurokinin, substance P, luteinizing hormone- and 
thyroid-stimulating hormone receptors 63. G protein-coupled receptors (GPCRs) consist of a single 
peptide chain that threads back and fourth across the cellular lipid bilayer seven times giving rise to 
three intracellular and three extracellular loops, an extracellular N-terminus and a C-tail within the cell. 
Upon activation the intracellular face of the receptor interact with G proteins located at the intracellular 
side of the plasma membrane 64. After stimulation and coupling to various G proteins the PARs 
activate signal transduction pathways resulting in rapid transcription of target genes 65, se figure 1. 
Activated PARs also interact with various adaptor proteins that facilitate signal transduction 
independent of heterotrimeric G protein coupling, like β-arrestins and Jab1 (Jun activating binding 
protein-1) 66.  
 
The hallmark that singles out the PARs from other G protein-coupled receptor systems is the unique 
proteolytic activation mechanism that reveals a cryptic amino-terminal tethered ligand that folds back 
and activates the cleaved receptor 67. Rather than being activated by simple ligand occupancy the 
PARs are activated enzymatically through proteolysis of the receptor. Specific residues within the 
enzymatically revealed tethered ligand domain (about six amino acids) are believed to interact with 
extracellular loop 2 and other domains of the receptor resulting in activation 68, see figure 2a. Thus, 
PARs are not activated like “classical” receptors because the specific receptor-activating ligand is part 
of the receptor itself, whereas the circulating agonist is a relatively non-specific proteinase that does 





Figure 1   
G protein-mediated signalling by GPCRs 
In the classical view of G protein-coupled receptor (GPCR) signalling, receptor activation is achieved by agonist 
binding to extracellular and/or transmembrane regions of the receptor or protease cleavage of the N-terminal end 
in the case of PARs. The activated GPCR acts as a guanine nucleotide exchange factor, catalysing the exchange 
of GDP for GTP on the Gα subunit and inducing dissociation of the Gα and Gβγ subunits from each other and 
from the GPCR. Activated α-GTP subunits, of which there are multiple subtypes, including Gαs, Gαi, Gα12/13 and 
Gαq, subsequently bind to and regulate the activity of effectors such as adenylyl cyclase, RhoGEF and 
phospholipase Cβ (PLCβ). These modulate downstream effectors directly or by generating second messengers 
(such as cyclic AMP, diacylglycerol (DAG) and inositol-1,4,5-trisphosphate (Ins1,4,5P3) that modulate further 
downstream effectors, such as protein kinase A (PKA) and protein kinase C (PKC). Following their liberation from 
the heterotrimeric G protein complex, the βγ subunits can also bind to and regulate certain downstream effectors, 
such as ion channels and PLCβ.  




To date four PARs have been identified by molecular cloning; PAR1, PAR2, PAR3 and PAR4 
45; three 
are originally considered targets for thrombin (PAR1, PAR3, and PAR4) and a single receptor is 
originally thought to be targeted by trypsin and mast cell tryptase (PAR2). The proteolytic cleavage of 
PARs is primarily mediated by a well characterized family of enzymes that require serine within the 
active site; the serine proteases 45. Serine proteases are highly active mediators with diverse biological 
activities. So far, proteases have been considered to act primarily as degradative enzymes in the 
extracellular space. However, their biological actions in tissues and cells suggest important roles as a 
part of the body’s hormonal communication system during inflammation and immune response 65. 
Several proteases have been identified that are capable of activating each receptor and serine 
proteases may originate endogenously from the coagulation cascade, inflammatory cells, and the 
digestive tract or exogenously from invading pathogens and particle containing vectors like bio 
aerosols. Short synthetic peptides (PAR activating peptides; PAR-APs) based on the proteolytically 
revealed tethered ligand sequences can serve as selective receptor agonists 65, see fig 2b. Some 
PAR-APs activate more than one PAR, but some (like the PAR2-AP SLIGRL-NH2) are highly specific 
only being able to activate one PAR. 
 
The discovery of the PAR family initiated intensive investigations into the functions of these receptors. 
The general approach has been to map receptor distribution at the tissue and cellular level, and to 
examine the biological effects of PAR agonists in different systems. This approach has provided a 
large body of information that suggests that proteases and their receptors play important roles in 
tissue responses to injury, including inflammation, pain and healing. The use of genetically modified 
animals (PAR knockout and transgenic mice) in models of disease further supports an important role 





Mechanisms of PAR activation.  
(a) Activation of PAR signalling by proteinase-mediated cleavage of receptor N-terminus to reveal the tethered 
ligand (TL). (b) Activation of PAR signalling by exogenous application of synthetic PAR agonist peptide (AP) 
without the need for proteolytic revealing of the tethered ligand.  
(GPCR) G protein-coupled receptor, (PAR) proteinase-activated receptor, (h) human, (m) murine, (r) rat. 





The discovery of the thrombin receptor (PAR1) in 1991 prompted an intense search for similar 
receptors for other proteases. The search was fruitless until the serendipitous discovery of a receptor 
for trypsin by the Sundelin group in 1994. The receptor, now named PAR2, was identified by screening 
a mouse genomic library using degenerate primers to the second and sixth transmembrane domains 
of the bovine neurokinine 2 receptor 46, 71, 72. A clone was found that encoded a protein of 397 residues 
with the typical characteristics of a GPCR and with ~ 30% amino acid identity to human PAR1. 
Significant heterogeneity was observed in the extra membranous domains, including the C-terminal 
tail and the N-terminus that is 29 amino acids shorter than in PAR1 and lacks a hirudin-like thrombin-
binding domain 45. The receptor contained a potential cleavage site within the extracellular amino 
terminus of 46 residues that was favourable for trypsin. Indeed, trypsin was found to cleave the 
receptor at this arginine-serine bond to expose the tethered ligand domain responsible for activating 
the receptor 70.  
 
Mechanisms of activation 
 
As previously described, the general mechanism by which proteases cleave and activate PARs is the 
same: the proteases cleave at specific sites within the extracellular amino terminus of the receptors; 
this cleavage exposes a new amino terminus that serves as a tethered ligand domain which binds to 
conserved regions in the second extracellular loop of the cleaved receptor, resulting in initiation of 
signal transduction 45, 67, 73. There is currently no known function of the amino-terminal fragment of the 
receptor that is removed by proteolysis. Trypsin cleaves PAR2 at SKGR
36 
↓ S37LIGKV to reveal the 
amino-terminal tethered ligand S37LIGKV in humans and S37LIGRL in rat 46, 71. Several observations 
support this mechanism of activation; 1) Mutation of the cleavage site prevents trypsin cleavage and 
signalling, indicating the importance of this site for activation of PAR2. 2) Exposure of cells to trypsin 
results in loss of immunoreactivity to an antibody against an amino-terminal epitope, which indicates 
that trypsin cleaves intact PAR2 at the cell surface 
74.  
 
Synthetic peptides corresponding to the tethered ligand domain activate PAR2 without the need for 
receptor cleavage. Analyses of analogues of the PAR2 agonist peptide (AP) have identified the 
residues that are essential for biological activity. In general, the rat/mouse peptide SLIGRL is slightly 
more potent that the human agonist SLIGKV in activating both human and murine PAR2 
75. Only the 
first five amino acids of the PAR-activating peptides are critical and a short (four or five peptide 
residues) peptide motif appears to be sufficient for receptor activation 76. Analysis by alanine scanning 
indicates that Leu2 and Arg5 are essential for activity. Substituting the positive Arg5 with either an 
amino acid with a neutral side chain (alanine) or a negative side chain (glutamic acid) in the peptides 
SLIGAL or SLIGEL reduces their potency for activating PAR2 by at least 32-fold (SLIGAL) and 130-
fold (SLIGEL) measured by their ability to cause a rise in intracellular calcium signalling in transfected 
KNRK cells expressing wild type ratPAR2 constructs 
77. In addition to SLIGRL/SLIGKV there are 
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several other peptides that may activate PAR2 and their structure-activity relationship has been 
extensively studied in bioassay systems including tissue preparations (rat aorta relaxation, rat gastric 
longitudinal muscle contraction) and cell culture (human embryonic kidney 293 (HEK293) cell calcium 
signal) 76-78. The incorporation of an amide at the carboxy terminus of the receptor activating peptides 
increases peptide potency (SLIGRL-NH2 > SLIGRL) 
76, 79 as well as incorporating an N-terminal furoyl-
modifiaction to protect the peptide from endogenous aminopeptidases (2-furoyl-LIGRLO-NH2 
>>SLIGRL-NH2) 
80, 81. The relative potencies of the PAR2 selective agonist peptides in either a calcium 
signalling assay or aorta relaxation assay were found to be: 2-furoyl-LIGRLO-NH2 >> SLIGRL-NH2 ≈ 
trans-cinnamoyl-LIGRLO-NH2 > SLIGKV-NH2 > SLIGKT-NH2 
82.  
The PAR2 agonist peptides are selective for PAR2, but the fact that they are agonists only at relatively 
high peptide concentrations, unspecific effects not related to activation of PAR2 may occur. Because of 
this, the search for agonists displaying higher potencies is continuous. Recently, two small-molecule 
PAR2 agonists have been reported; AC-55541 (N-[[1-(3-bromo-phenyl)-eth-(E)-ylidene-
hydrazinocarbonyl]-(4-oxo-3,4-dihydro-phthalazin-1-yl)-methyl]-benzamide) and AC-264613 (2-oxo-4-
phenylpyrrolidine-3-carboxylic acid [1-(3-bromo-phenyl)-(E/Z)-ethylidene]-hydrazide) 83. They each 
represent a distinct chemical series and show similar potency as 2-furoyl-LIGRLO-NH2, the most 
potent PAR2 agonist peptide so far. 
 
Identification of the docking interactions between tethered ligand domain and receptor is critical for 
understanding transmembrane signalling by these receptors. Along with studies investigating agonist 
peptide potencies, analyses of mutant and chimeric receptors and of analogs of APs have identified 
critical residues of the tethered ligand domains that interact with binding domains of the PARs 
(extracellular loop II) and which are thus essential for signal transduction. Interactions between the 
tethered ligand of PAR2 and the cleaved receptor have been examined by studying chimeras of PAR1 
and PAR2 and shows that the primary determinant of agonist specificity is extracellular loop 2 (ECL2) 
84. Receptor chimera studies of the human-Xenopus PAR1 receptor suggest a possible interaction 
between Arg5 in SFLLRN and Glu260 in the second extracellular loop of the PAR1 
85, 86. These amino 
acids are also conserved in PAR2. Thus, an Arg
5-Glu260 interaction might also operate in recognition of 
the PAR2 agonist peptide SLIGRL by PAR2.  
The important role of residues in ECL2 of PAR2 for interaction with tethered ligand peptides has also 
been revealed by the study of mutant receptors and analogs of the PAR2 agonist peptides 
87. An acidic 
region (PEE) that is just distal to a highly conserved domain (CHDVL) makes an important contribution 
to determining the selectivity of PAR2 agonists, but seems not to have as marked an effect on receptor 
activation by the trypsin-revealed tethered ligand as for activation by free peptides. However, the 
different specificities that is shown for PAR1 and PAR2 (the PAR1 agonist peptide SFLLRN is able to 
activate PAR2 as well as PAR1, while the PAR2 agonist peptide SLIGRL only activates PAR2) suggests 
that other direct or indirect interactions between agonists and ECL2 must be responsible for 
distinguishing the PAR1 and PAR2 receptor agonists. In addition to the interaction between the 
tethered ligand at the amino terminal end (or agonist peptide) and ECL2, other extracellular domains 
of PAR2 like ECL3 and the amino terminal end may be important in agonist recognition and research 
indicates that they must interact, directly or indirectly, for proper receptor function 84.  
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Research has also shown differential activation of PAR2 by the tethered ligand and soluble peptide 
analogs. Rat PAR2 receptor mutants in which the positive arginine at position 41 of the revealed 
tethered ligand (corresponding to Arg5 in the soluble peptide analogue SLIGRL) is changed to either a 
neutral alanine or a negative glutamatic acid will correspond to the synthetic receptor analogues 
SLIGAL and SLIGEL when revealed by trypsin cleavage. Compared to the wild type receptor these 
mutated receptors give equivalent responses in intracellular calcium signalling when activated by 
trypsin. Bearing in mind the fact that the soluble peptide analogues SLIGAL and SLIGEL had marked 
potency differences compared to SLIGRL, it can be concluded that for PAR2 activation, the trypsin-
revealed PAR2 tethered ligand sequence interacts differently for receptor activation that does the same 
peptide sequence as a free peptide 77. 
In addition to Arg5 in the agonist peptide, the first two amino acids of the trypsin-revealed tethered 
ligand in ratPAR2 (Ser
37Leu38) were found to be important in an intracellular Ca2+ signalling assay 88. 
Here the revealed rat PAR2 mutated TL sequence SLAAA-, was able to stimulate increase in 
intracellular Ca2+, whereas the mutated TL sequences LSIGRL- and AAIGRL- were not. In addition, 
the work showed that whereas the sequence SLAAA- could activate calcium signalling as a tethered 
ligand, the corresponding soluble peptide SLAAA-NH2 was unable to do so. These data points to 
differences in signal trafficking by PAR2 depending on whether it is activated by its own proteolytically 
revealed TL or by an analogous synthetic peptide. 
The Hollenberg group has also shown that even though the ability of the revealed tethered ligand to 
stimulate an elevation in intracellular calcium is lost when the S37L38-sequence is mutated to alanines 
or switched in sequence to L37S38, the activation of MAP kinase is retained. This biased signalling with 
a triggering of MAP kinase but not calcium is also observed for the synthetic PAR-activating peptide 
SLAAA-NH2, and its ability to interact with the receptor seems to differ from that of the same sequence 
when presented to the receptor as a trypsin-revealed tethered ligand, which activates both calcium 
and MAP kinase signalling 89. For many other GPCRs, such as those for angiotensin II, dopamine, 
serotonin, and adrenergic ligands, it is now accepted that there can be differential signalling, 
depending on the activating ligand. This agonist-dependent differential signalling has been termed 
“agonist-biased signalling” or “functional selectivity” 90-93.  
 
Although PAR2 originally is considered to be activated by trypsin, other proteases are capable of 
cleaving the PAR2 N-terminal tail under experimental conditions. However, posttranslational 
modifications of the receptor may influence on the ability of different proteases to cleave and activate 
PAR2. PAR2 is shown to contain at least two sites for N-linked glycosylation: Asn
30; 6 residues 
proximal to the cleavage and activation site, and Asn222 in ECL2. The potency by which tryptase (but 
not trypsin) activates PAR2 is dramatically increased by mutation in one of the glycosylation sites 
(Asn30), by enzymatic deglycosylation, or by expression of PAR2 in glycosylation-defective cells 
94, 95. 
Thus, glycosylation of the receptor at a site close to the activation site markedly impairs the capacity of 
tryptase to signal. The reason for this finding is currently unknown, but glycosylation could impede 
access of the amino terminus of PAR2 to the active site of tryptase. An important aspect is to 
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determine if the receptor is similarly glycosylated in tissues and to know if there are mechanisms that 
deglycosylate the receptor. 
 
Multiple proteases activate PAR2 
 
The capacity of a protease to signal in intact tissues depends on many factors 73; 
First, the protease(s) must be generated or released in sufficient concentrations to activate PAR2. 
Although the catalytic properties of proteases would ensure that even very low concentrations could 
eventually cleave all receptors on the surface of the cell, it is the rate of hydrolysis of PARs that 
determines the magnitude of the resulting cellular signal 96. Second, efficient hydrolysis and activation 
of PAR2 may require the presence of accessory co-factors, for example tissue factor (TF) in the case 
of FVIIa-FXa receptor activation. Finally, the capacity of a protease to signal will depend on the 
availability of protease-inhibitors that serve to dampen the effects of many proteases in vivo. Although 
trypsin is a very potent activator of PAR2 in cultured cells, trypsin inhibitors are widely expressed and 
may well limit the capacity of trypsin to signal in intact tissues. Remembering these caveats, many 
proteases have been identified that are capable of activating PAR2 in different cell lines under 
experimental conditions, but the endogenous activator of PAR2 is uncertain in most situations 
73.  
 
1) Pancreatic and extrapancreatic trypsins  
There are at least three distinct trypsin genes in humans: trypsin I (cationic trypsin), trypsin II (anionic 
trypsin), and mesotrypsin. Trypsin I 71, 97, trypsin II 98 and trypsin IV (a splice variant of mesotrypsin) 
99 are all found to be capable of activating PAR2. Trypsins are widely distributed enzymes that are 
expressed by pancreatic as well as extrapancreatic cells including endothelial cells 100, epithelial cells, 
leukocytes, and cells in the nervous system 101 and in tumors 102, 103.  
The potential of trypsins to signal to cells by cleaving PAR2 depends on the release of the zymogen 
trypsinogen, the presence of enteropeptidase (which activates trypsinogen), and the existence of the 
large array of endogenous trypsin inhibitors. Luminal trypsin (trypsin I and II) in the small intestine 
reach a concentration of 1 µM in feeding rat, a concentration which is more than capable of strongly 
activating PAR2 at the apical surface of enterocytes (EC50 ~ 5 nM) 
104. Trypsin II isolated from 
conditioned medium from colon cancer cell lines can cleave and activate PAR2, and since these cells 
express PAR2 it is theoretically possible that trypsin II could regulate cells in an autocrine manner 
105. 
Pancreatic trypsinogens are also prematurely activated in the inflamed pancreas where they are 
released into the interstitial fluid and vasculature and could activate PAR2 in pancreatic acini, duct 
cells, and nerves 106. Trypsinogen IV is invariably co expressed with PAR2 in epithelial cell lines, 
endothelial cell lines, and human colonic mucosa and trypsin IV cleaves and activates PAR2 
73. Of 
particular interest is that trypsin IV is resistant to most proteinaceous trypsin inhibitors that effectively 
inhibit trypsins I and II 107. In the airways trypsinogen is found to co-localize with PAR2 in Clara cells of 
the epithelium and to be expressed by cells just above the basal layer of human bronchioles 108, 109. 
Trypsin II is found to co-localize with PAR2 in bronchoalveolar epithelium from preterm infants with 
acute and chronic lung injury 110. Human airway trypsin-like protease (HAT) is a monomeric serine 
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protease that is found specifically in ciliated epithelial cells of the airways 111, 112. HAT is shown to 
activate PAR2 in primary human bronchial epithelial cells and human bronchial fibroblasts 
113, 114. The 
results from Cocks 108, 109 and Cederqvist 110 strongly suggest that a trypsin-like substance is present in 
the airway epithelium; however, in immunohistochemistry cross-reactions may occur and raises 
uncertainty whether the trypsin immunoreactivity is caused by trypsin itself or other trypsin-like 
substances like HAT. 
 
2) Mast cell tryptase  
There has been considerable interest in mast cell tryptase (MCT) as an activator of PAR2. Tryptase is 
the most abundant protease of human mast cells – it comprises up to 25% of the total cellular proteins 
and is expressed by almost all subsets of human mast cells 115. Human mast cells express at lest five 
distinct tryptase genes: α, βI, βII, βIII and transmembrane tryptase, and splice variants also exist. Mast 
cell tryptase purified from human lung is shown to cleave a peptide based on the PAR2 cleavage site, 
suggesting that this protease is a potential physical activator of PAR2 
116. Trian and co-workers (2006) 
have shown by RNA interference that tryptase activates PAR2 in human airway smooth muscle cells 
117. Many of the proinflammatory and mitogenic effects of tryptase are mimicked by PAR2-APs and 
absent in cell types not expressing PAR2. This suggests that tryptase exerts its effects through PAR2 
in various cell types, though the molecular form of tryptase responsible for the observed PAR2 effects 
in each case is largely unknown 57, 118-123. However, tryptase is considerably less potent than trypsin. 
Because tryptase is a large and poorly diffusible protease (a 134 kDa tetrameric protease in the form 
of a flat ring of four monomers), it is likely that tryptase signals in a paracrine manner to cells that are 
in close proximity to mast cells, such as sensory nerves that express PAR2, which participate in 
inflammation and pain 124-126. There is evidence for the fact that tryptase can activate PAR2 in vivo 
under conditions of inflammation and mast cell activation when large amounts of tryptase are released 
close to PAR2 expressing cells. Thus, injected tryptase has proinflammatory and hyperalgesic actions 
in mice that are not observed in PAR2-deficient animals 
126, 127.  
 
3) Cell-surface proteases 
Certain anchoring proteins may serve as co-factors that facilitate the capacity of certain proteases to 
activate PARs, but proteases that are themselves integral membrane proteins can also activate PAR2. 
Membrane-type serine protease 1 (MT-SP1) is a type II integral membrane protein with an 
extracellular protease domain 128. Analysis of the substrate specificity of MT-SP1 suggests PAR2 as a 
potential substrate, and both MT-SP1 and PAR2 are co-expressed at the surface of certain cell types 
(e.g. PC-3 cells). It remain to be determined if the membrane-bound MT-SP1 can activate PAR2 under 
more physiological circumstances. 
 
4) Coagulation factors 
Serine proteases from the coagulation cascade are perhaps the best characterized activators of PARs 
as thrombin has been extensively studied as an intrinsic agonist that activate PAR1, PAR3, and PAR4 
at the surface of platelets resulting in aggregation, a process which contributes to hemostasis 129. 
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Coagulation factors VIIa (FVIIa) and Xa (FXa) are proteases that act upstream of thrombin in the 
coagulation cascade and require co-factors to interact with their substrates. These proteases elicit 
cellular responses, but their receptor(s) have not been identified. The tissue factor (TF)-FVIIa-FXa 
complex may signal by cleaving PAR2 on epithelial (keratinocytes) and endothelial cells, the latter of 
particularly importance in inflammation 130, 131. This activation is dependent on the presence of 
accessory proteins and coagulation factor VIIa (FVIIa) activates PAR2 only in cells that also express 
tissue factor (TF), an integral membrane protein which binds and concentrates factor VIIa at the cell 
surface in the vincity of PAR2 
130. The FVIIa/TF complex also generates factor Xa (FXa) from FX at the 
cell surface, which facilitate PAR2 activation.  
 
5) Tumor-derived proteases: kallikreins 
The family of kallikreins (KLKs) has attracted substantial attention as a group of serine proteases 
linked to cancer-associated pathophysiology 132, 133. The human KLKs, which are secreted as inactive 
zymogens, can exhibit either trypsin (twelve family members) or chymotrypsin-like (three family 
members) activity upon proteolytic activation 133. Although the KLKs are differentially expressed in 
cancer and other diseases in relation to normal tissues 132-134, little information exist about the 
functions that these enzymes might play in vivo 135. Recent work by Oikonomopoulou and co-workers 
(2006a,b) hypothesize that the tissue kallikreins can signal to cells by cleavage and activation of PARs 
136, 137. KLK5, 6 and 14 are all found to cleave synthetic peptides representing the cleavage-activation 
sequences of PAR2 and cause increase in intracellular Ca
2+ in target cells. There are distinct 
differences between the three tested kallikreins in terms of their selective actions on each of the PARs. 
KLK14 activate both PAR2 and PAR4, and may activate or inactivate PAR1, while KLK5 and 6 
preferentially activate PAR2. Like trypsin, all three KLKs can activate vascular endothelial PAR2 (rat 
aorta) to cause NO-dependent relaxation 136. Further work is required to evaluate the potential 
inflammatory and nociceptive roles that KLKs may play. Because of their ability to regulate tissues via 
PARs, their wide expression in regions where trypsins may not be produced and their possible 
participation in enzymatic cascades, the KLKs represent important potential physiological regulators of 
tissue function in vivo 135.  
 
6) Other mammalian enzymes 
A tryptic-like serine protease purified from rat brain, P22, degrades matrix and can signal to cells by 
activating PAR2 
138. Acrosin, a trypsin-like serine protease found in large quantities in the acrosomal 
body of spermatozoa of all mammals activate PAR2 in stably transfected Chinese hamster ovary cells 
139. Furthermore, airway epithelium expresses acidic mammalian chitinase 140 which may be a possible 
activator of PAR2 as chitinase from Streptomyces griseus is shown to activate PAR2 in human airway 
epithelial cells 141. Mammalian chitinase is thought to be a mediator of disease manifestation in an 





7) Non-mammalian proteases 
A number of non-mammalian proteases from mites, bacteria, mold/fungi, cockroaches and fish have 
been found to signal to mammalian cells by cleaving PARs 1, 38-41, 141-150. Although many of the 
exogenous proteases that activate PAR2 are serine proteases, other proteases like the cysteine- and 
metalloproteases are also found to be capable of activating PAR2. 
The dust mites Dermatophagoides pteronyssinus and Dermatophagoides farinae produce a series of 
proteinases that are allergens in the airway epithelium. Der P3 and Der P9 are serine proteases that 
can cleave fragments of PAR2 at the activation site, and desensitization experiments suggest that the 
effects of these proteases on airway epithelial cells are mediated in part by PAR2 
149. The bacteria 
Porphyromonas gingivalis is a major mediator of periodontitis in humans, and bacterial arginine-
specific gingipains-R (RgpB, a cysteine protease) can activate PAR2 transfected cells in an oral 
epithelial cell line to induce release of the powerful proinflammatory cytokine IL-6 40. Thermolysin 150, 
serralysin from Serratia marcescens 38 (both metalloproteases) and LepA from Pseudomonas 
aeruginosa (large exoprotease with a trypsin-like serine protease motif) 39 are additional bacterial 
proteases that are found to activate PAR2 in experimental settings including HBE (human bronchial 
epithelial cells) and EBC-l cells (human lung squamous cell carcinoma). Chitinase (a hydrolase) from 
Streptomyces griseus is a potent proteolytic activator of PAR2 and directly induce PLC/IP3-dependent 
Ca2+ signalling in human airway epithelial cells 141. Additionally, extracts from Aggregatibacter 
actinomycetemcomitans are shown to induce secretion of IL-8 and expression of ICAM-1 via PAR2 
activation in gingival epithelial cells 41. 
The mold allergen and serine protease, Pen c 13 is the immunodominant allergen produced by 
Penicillium citrinum and induces IL-8 expression in human airway epithelial cells (A549) by activating 
PAR2 (and PAR1) 
142. 
PAR1 and PAR2 contribute to inflammation and immunity to the fungi Candida albicans and Aspergillus 
fumigatus. Activation of Toll-like receptors (TLRs) by fungi has unmasked an essential and divergent 
role for PAR1 and PAR2 in downstream signalling and inflammation. TLRs activate PARs and triggers 
distinct signal transduction pathways. Inflammation was promoted by PAR2 activation in response to 
Candida and by PAR2 inhibition in response to Aspergillus 
146. 
Serine proteases from cockroach activate PAR2 in human bronchial epithelial cells 
147, 148, human 
keratinocytes 143, and mouse lung fibroblasts 144 and regulate IL-8 expression via nuclear factor for 
interleukin-6 (NF-IL6) and extracellular-signal regulated kinase (ERK) in human bronchial epithelial 
cells. PAR2 activation by cockroach allergens is also shown to delay epidermal permeability barrier 
recovery in murine skin 143.  
Purified salmon trypsin is shown to induce secretion of IL-8 from cultured airway epithelial cells 
(A549), an effect mediated by activation of PAR2 as knockdown of PAR2 by the use of siRNA almost 
completely abolishes the dose-dependent IL-8 release. Purified salmon trypsin is also found to 
promote DNA-binding of the transcription factor NF-κB via activation of PAR2. These findings suggest 
that purified salmon trypsin behaves similarly to mammalian trypsin regarding the ability to activate 
PAR2, but closer comparisons have not been made 
1. In addition, trypsins from sardine and king crab 
are shown to cleave and activate PAR2. Both sardine and king crab trypsin induces the secretion of IL-
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8 from human airway epithelial cells (A549), an effect at least partly mediated by PAR2, but displays 
individual differences in transformation of the NF-κB signal 145. 
 
Proteolytic inactivation of PAR2 
 
Some proteases are also shown to be capable of inactivating PAR2 by cleaving the N-terminal of the 
receptor in a way that does not produce an activating tethered ligand sequence, leaving the receptor 
refractory to subsequent activation by other proteases. Additionally, proteases that cleave the binding 
domain in extracellular loop II would generate unresponsive receptors.  
Neutrophil elastase (NE), cathepsin G (CG), and proteinase 3 (PR3) are serine proteases stored in the 
azurophilic granules of polymorphnucleated neutrophils (PMN). They participate in destruction of 
invading microorganisms, but can also proteolyze endogen components like extracellular matrix and 
immune effector proteins when released in excessive amounts. NE and CG are shown to disarm PAR2 
most likely by cleavage at sites downstream of the activation site in human respiratory epithelial cells 
(16HBE, A549) 151, 152. Although not tested in cell lines, PR3 is shown to cleave the extracellular N-
terminal fragment of PAR2 at disabling sites downstream from Ser
37 like NE and CG 152. 
In addition to the endogen proteases originating from neutrophils, elastase from Pseudomoas 
aeruginosa (EPa, an elastolytic metalloprotease also termed LasB or pseudolysin) is shown to disable 
PAR2 in respiratory epithelial cells 
153. EPa cleaves the N-terminal domain of PAR2 from the cell 
surface without triggering receptor endocytosis as trypsin does. This cleavage does not activate PAR2 
(evaluated by measurement of cytosolic calcium, PGE2, and IL-8 production), but rather disarms the 
receptor for subsequent activation by trypsin, but not by the synthetic receptor-activating peptide, 
SLIGKV-NH2. Proteolysis by EPa of synthetic peptides representing the N-terminal cleavage/activation 
sequences of either human or rat PAR2 indicates that cleavages resulting from EPa activity (at Ser
37 – 
Leu38 and Gly52 – Val53) would not produce receptor-activating tethered ligands, but would disarm 
PAR2 in regard to any further activating proteolysis by activating proteases. Thermolysin is also shown 
to render PAR2 refractory to trypsin but not agonist peptide stimulation in A549, suggesting that this 
bacterial metalloprotease might disable PAR2 in this cell type compared to the human bronchial 
epithelial cell line where it is shown to activate the receptor 150. 
 
Some proteases can cleave PARs at several sites, including activation and disabling sites, and the net 
result depends on the efficiency of cleavage at different locations. Tryptase can cleave PAR2 both at 
the activation site (Arg36 – Ser37) and at the Lys41 – Val42 site which could inactivate the receptor 122. In 
this case, the activating cleavage is more important since tryptase is found to be a PAR2 activator. 
This dual cleavage is presumably a concentration-dependent effect as tryptase at 1 nM cleaves the 






PARs are frequently co-expressed and interactions between receptors in the same cell can have 
important functional consequences 73. GPCRs can form homodimers and heterodimers with important 
consequences for signal transduction. Although the principal mechanism of PAR activation is 
intramolecular (the unmasked tethered ligand binds to the cleaved receptor), there are several 
examples of intermolecular interactions between different PAR molecules. Intermolecular signalling, 
by which a cleaved receptor can activate an uncleaved receptor, was first demonstrated for PAR1 
154. 
There is also evidence of intermolecular signalling between different PARs and peptides 
corresponding to the tethered ligand of PAR1 (SFLLRN) are shown to activate PAR2, but not vice 
versa 75. Research has also shown that cleaved PAR1 receptor is able to interact with and signal 
through uncleaved PAR2 
155. This novel form of intermolecular signalling between different PARs 
clearly requires the close association of receptors at the cell surface, which could be influenced by 
levels of expression or by anchoring proteins that may affect mobility of receptors in the membrane 73. 
 
PAR2 is also shown to interact with other receptors besides its family members. In mouse and man, 
the TLRs represent a family of > 10 single-transmembrane classical pattern-recognition receptors 
(PRRs) that detect chemically conserved microbial components, for example, lipopolysaccharide 
(LPS), lipopeptides, and RNA 156-158. Innate immunity has largely been attributed to the capacity of 
PRRs to respond to conserved pathogen-associated molecular patterns (PAMPs), whereas PARs 
have generally been considered to be “sensors” of the extracellular proteolytic environment.  
In transiently transfected HEK293 cells and a non-transfected colonic epithelial cell line (SW620), 
PAR2 is found to interact with Toll-like receptor 4 (TLR4) showing a synergistically response to PAR2 
agonist peptide and LPS 159. PAR2 and TLR4 are believed to form a heterophilic receptor interaction 
that centers on shared utilization of TLR adapter proteins, leading to intracellular signalling (NF-κB 
activation) upon PAR2 engagement with agonist peptides. The synergistically NF-κB activation is 
found to be MyD88-dependent, one of two major signalling pathways activated by TLR4. 
PAR2 activation is also found to deliver intracellular signals that intersect with TLR/IL-1R (interleukin-1 
receptor) signalling pathways 159-162. Cooperation between PAR2 and TLR2, TLR3, or TLR4 for NF-κB-
dependent IL-8 mRNA induction is observed in the mucosal epithelial cell lines A549 (human airway 
epithelial cells) and SW620 (colon epithelial cells). PAR2 is also shown to execute negative regulation 
of the TLR3 antiviral pathway 163. This collaboration between PAR2 and TLRs imply a previously 
under-appreciated role of PARs as an additional level of the innate immune defence, apart from the 
classical pattern-recognition receptors.  
Furthermore, PAR2 is shown to transactivate epidermal growth factor receptor (EGF-R) in a human 
colon cancer cell line and intestinal epithelial cells stimulated with both trypsin and PAR2 agonist 
peptide, resulting in cellular proliferation through ERK 1/2 activity 164, 165. These results indicate that 
PAR2 may play a role in the control of tissue growth through promotion of cellular proliferation in colon 
cancer. Additionally, the oncogene variant of EGF-R is associated with increased expression of PAR2, 
yielding tumour cells that are hypersensitive to contact with blood borne proteases and contribute to 





Although the knowledge of PAR2 signalling pathways is more limited than the existing information on 
PAR1 mediated signalling events, ongoing research constantly reveal new information regarding PAR 
signalling. With respect to the coupling of PAR2 to the various G proteins, the existing information does 
not originate from airway cells. However, when describing the signal transduction cascades 
downstream of G proteins, I will focus on current knowledge about PAR2 mediated signalling in airway 
cells. Still, it has to be kept in mind that the various signalling events following receptor activation may 
differ between different cell lines/types even though they all originate from the airways. For more 
information about PAR2 signalling events in other cell types/tissues the readers are referred to reviews 
from MacFarlane et al 2001 45, Coelho et al 2003 70, Ossovskaya and Bunnett 2004 73, Steinhoff et al 
2005 65, and Ramachandran and Hollenberg 2008 47. 
 
Signal transduction following receptor activation commences with coupling of PARs to heterotrimeric G 
proteins at the plasma membrane, often called transducers of the signal. The activated G protein 
subunits (α and βγ) can then associate with downstream effectors to modulate various aspects of 
cellular physiology. PAR1 is known to couple with multiple G proteins, including Gαq, Gαi, and Gα12/13 
families 45, 65, but our knowledge of PAR2 interactions with G proteins and subsequent intracellular 
signalling has been studied in less detail. It is likely that PAR2 couples to Gαq since PAR2 activators 
stimulate the generation of inositol-tris-phosphate (IP3) along with diacyl-glycerol (DAG) and 
subsequent intracellular Ca2+ mobilization in PAR2 transfected cells and several cell types including 
enterocytes, kerationocytes, myocytes, neurons, astrocytes and tumor cells 46, 71, 97, 104, 119, 120, 167, 168. 
Pertussis toxin-sensitive Ca2+ signalling has been demonstrated in Xenopus oocytes in response to 
trypsin indicating a potential involvement of Gαi 
45, 169. However, trypsin stimulation rendered PAR2 
signalling unaffected by pertussis toxin in PAR2 transfected cells and enterocytes, suggesting that it 
does not signal through Gαi in these cells 
170. McCoy and co-workers (2010) have shown that in 
contrast to PAR1, all of the Gαi subunits binds only weakly or not at all to PAR2 in transfected COS-7 
cells and wild type Neu7 astrocytes 171. The same study reports the formation of a stable complex with 
PAR2 and Gα12/13 that leads to Rho A activation following agonist peptide stimulation.  
The coupling of PAR2 to G proteins may very well differ in different cell types and tissues, and under 
different conditions. Additionally, one agonist stimulating PAR2 may lead to activation of different 
signalling pathways (eks intracellular Ca2+ signalling and MAP kinase activation) that depends upon 
coupling of distinct G proteins to the activated receptor. The generation of intracellular Ca2+ signalling 
following trypsin stimulation in rPAR2 transfected KNRK cells is G αq-mediated, whereas MAP kinase 
activation in the same cell type following trypsin stimulation is only partially G αq-dependent but seems 
to be dependent on G α12/13 coupling and Rho activation 
89. 
 
Interestingly, PAR2 has been shown to be able to signal via an arrestin-mediated process that can be 
independent of G protein interactions in mouse embryonic fibroblasts and a human breast cancer cell 
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line 172. This G protein independent signalling might involve PAR heterodimers (for example 
PAR2/PAR1) and may explain the “dual” actions that PAR2 displays in certain settings, triggering either 
inflammatory or anti-inflammatory responses. Furthermore, PAR2 is shown to promote the formation of 
a complex containing β-arrestins, cofilin and chronophin (the upstreams activator of cofilin) in primary 
leukocytes and cultured cells (mouse embryonic fibroblasts and human breast cancer cells), a 
complex that is important in leukocyte chemotactic migration by directing localized actin filament 
severing and membrane protrusions 173. In addition to the β-arrestins, PAR2 has been reported to bind 
to the Jun activating binding protein-1 (Jab1), a protein that stabilizes complexes of the AP-1 family 
members c-Jun and Jun D with their DNA-binding sites 174. The binding of Jab1 and PAR2 induce 
activation of the transcription factor c-Jun and subsequent gene transcription. 
 
Following activation of the G proteins, primary effectors generate secondary messenger molecules like 
IP3, DAG and Ca
2+ creating signals that can diffuse within the cell by activating secondary effectors 
and other downstream signalling components. PAR2 activation is shown to turn on the primary and 
secondary effectors phospholipase C 175 and protein kinase C 176 in human airway smooth muscle and 
human airway epithelial cells (A549) respectively. Active phospholipase C might be due to PAR2 
activation in human airway epithelial cells (A549) stimulated with the mold allergen Pen c 13 142. 
Recently, it has been revealed that regions within the PAR2 C-terminal tail are critical for 
phospholipase C-mediated IP3 formation and Ca
2+ signalling as opposed to the activation of MAP 
kinase that is triggered by other intracellular PAR2 sequences 
177.  
The MAPK cascade consists of various pathways involving multiple kinases and ERK 1/2 activation 
has been connected to PAR2 in the airways by stimulating human bronchial epithelial cells 
(16HBE14o) 147 and human airway epithelial cells (A549) 176, 178, 179 with selective PAR2 peptides. 
Human airway trypsin-like protease (HAT) is found to stimulate primary human bronchial fibroblasts 
through a PAR2-dependent MEK/ERK1/2 mediated pathway 
113. The activation of ERK 1/2 signalling is 
facilitated by PAR2 binding to and co-internalizing with β-arrestins in endocytic vesicles, an event that 
mediates changes in the actin cytoskeleton and cell migration 170, 180 as well as contributing to the 
formation and secretion of IL-8 and PGE2. In addition to ERK 1/2, PAR2 is shown to trigger 
phosphorylation of p38 and JNK in human airway epithelial cells (A549) 176, 178, 179, 181. Furthermore, 
PAR2 activation is shown to up-regulate phospholipase A2 (PLA2) and cyclooxygenase-2 (COX-2) in 
A549 cells, an effect shown to trigger the formation of PGE2 
176. The PAR2 triggered PGE2 formation 
as well as IL-8 secretion in A549 cells is also shown to involve the Src family tyrosine kinase and the 
epidermal growth factor receptor tyrosine kinase (EGFR-TK) 176, 181, mediators that links PAR2 to the 
transactivation of EGFR.  
The activation of intracellular signalling pathways leads to the generation of various products, both 
molecules that acts intracellularly and secreted molecules with autocrine, paracrine and endocrine 
effects. The production of these effectors involves gene transcription, a process initiated and 
controlled by transcription factors. PAR2 mediated activation and DNA-binding of NF-κB has been 
demonstrated in human airway epithelial cells (A549) 1, 178, 182. The PI3K/Akt pathway is capable of 
activating I-κB kinase α (IKKα), followed by phosphorylation of I-κB and activation of NF-κB in TNF 
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stimulated cells (transfected HEK293) 183. Moriyuki and co-workers (2009) have shown that the 
PI3K/Akt pathway is involved in the PAR2-triggered NF-κB signalling in human airway epithelial cells 
(A549), and that the PAR2 triggered phosphorylation of Akt is partially suppressed by MEK-inhibition 
184. Apart from NF-κB, CREB (cAMP responsive element binding protein) has been shown to be 
downstream of ERK 1/2 and mediate up-regulation of COX-2 through the β-catenin/T cell factor 
transcription pathway following PAR2 activation in A549 cells 
185. This PAR2 up-regulated COX-2 
expression reveal new cellular mechanisms by which serine proteases may participate in chronic 
mucosal inflammation and associated conditions. Phosphorylation of CREB is also shown to be 
involved in PAR2 induced PGE2 release from A549 cells through up-regulation of COX-2 
184.  
In addition to NF-κB, activation of PAR2 is shown to facilitate DNA-binding of the transcription factor 
AP-1 in human airway epithelial cells (A549) 178 and of NF-IL6 in human bronchial epithelial cells 
(16HBE14o) 148. The binding of NF-κB is shown to be essential for the induction of IL-8 gene 
transcription, while these two latter transcription factors (AP-1 and NF-IL6) are shown to be essential 
for maximal production of IL-8 186-189.  
Besides signal transduction leading to the release of cellular mediators, PAR2 activation is reported to 
enhance neutrophils adhesion to alveolar epithelial cells (A549), presumably in part by stimulating 
Rho/Rho-associated kinase (ROCK) signal-mediated actin cytoskeleton reorganization associated with 
thyrosine phosphorylation of focal adhesion kinase (FAK) 190. 
 
Termination of the signal 
 
Proteases activate PARs by an irreversible mechanism: cleavage exposes a tethered ligand domain 
that would be constantly available to interact with the receptor. Activation would then result in 
prolonged signalling unless there were efficient mechanisms to attenuate the response. Although the 
molecular mechanisms and pathways of agonist-induced trafficking of PARs can vary from receptor to 
receptor and in different cells 73, some common factors seem to apply.  
The intracellular signal following PAR activation can be terminated by receptor desensitization, 
which takes place by uncoupling of the G proteins from the intracellular domain of the cleaved and 
activated receptor. In addition to the desensitization process that shuts off an already activated 
signalling pathway, the cells can also determine their responsiveness to agonists by regulating the 
levels of receptors that are expressed at the plasma membrane and which are thus accessible to 
agonists in the extra cellular fluid. Accordingly, down regulation of receptor expression is a second 
way of terminating a signal by rendering the cells non-responsive to the agonist.  
 
The desensitization mechanism that terminates signalling by PARs is broadly similar to the classical 
pathway of desensitization that has been described in detail for many other GPCRs (particularly 
rhodopsin and the β2-adrenergic receptor) 
191; ligand occupation of the GPCR induces the 
translocation of members of the family of G protein receptor kinases (GRKs) from the cytosol to the 
activated receptor at the cell surface. GRKs are serine-threonine kinases that phosphorylate activated 
GPCRs, usually within the carboxy terminus or third intracellular loop. This phosphorylation triggers 
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the membrane translocation of arrestins which interact with the phosphorylated GPCR, disrupt 
association with heterotrimeric G proteins, and thereby terminate signal transduction. Besides GRKs, 
this desensitizing C-tail phosphorylation can be mediated by other protein kinases like protein kinase A 
(PKA) and protein kinase C (PKC), although this process seems not to involve β-arrestin recruitment 
to the receptor 192, 193. However, there remain many critical aspects of desensitization of GPCRs, 
including PARs, which are unexplored. In many cases, the GRK and arrestin isoforms that are co-
expressed with receptors in question and which mediate desensitization to physiological stimuli are 
largely unknown. Mechanisms of desensitization also vary between different PARs, probably due to 
structural differences, especially in the intracellular loop 2 and carboxy terminus.  
With regards to PAR2, phosphorylation at serine and threonine residues in the C-tail domain is shown 
to distinctly regulate and to be critical for receptor desensitization, β-arrestin binding, and endocytic 
trafficking 170, 194. The specific kinases responsible for C-tail phosphorylation of activated PAR2 is not 
identified, but PKC appears to play a role in regulating the PAR2 signalling 
74, 170. Activation of PKC 
abolishes PAR2-induced Ca
2+ signalling in transfected cell lines and enterocytes that naturally express 
this receptor, whereas PKC inhibitors magnify responses to PAR2 activators. Mutation of a putative 
PKC site in the carboxy tail of the receptor renders it unresponsive to inhibition by active PKC 170. 
 
The level of expression of receptor at the cell surface is a balance between removal by endocytosis 
and replenishment by recycling or mobilization of intracellular pools. PARs, which once cleaved, 
cannot be reused by the cell and are destined for intracellular degradation once internalized by 
endocytosis. This process will irrevocably terminate the signal and recovery requires synthesis or 
mobilization of new receptors.  
PAR2 activation is shown to induce translocation of β-arrestins to the plasma membrane where they 
interact with PAR2 to mediate both desensitization and endocytosis 
170, 195. Endocytosis of PAR2 
proceeds by a clathrin-mediated mechanism and the activated PAR2 is trafficked to lysosomes for 
degradation 66, 74, 195. The importance of β-arrestins in endocytosis of PAR2 is investigated by the use 
of mutated β-arrestin (mutation comprises the clathrin binding domain) that prevents endocytosis, and 
a mutated PAR2 that fails to internalize due to its inability to interact with β-arrestins in transfected cells 
89, 194. In mouse embryonic fibroblasts deficient in β-arrestin 1 and 2 expression, PAR2 desensitization 
was significantly impaired and internalization of PAR2 virtually abolished compared to wild-type β-
arrestin expressing cells 180. Thus, PAR2 appear to belong to the class B GPCRs that form high-affinity 
interactions with arrestins although phosphorylation-deficient PAR2 mutants has been shown to be 
capable of constitutive internalization independent of β-arrestins 194. The adaptor protein that mediates 
this constitutive β-arrestin-independent internalization is not known. Furthermore, Ramachandran and 
co-workers (2009) have shown that PAR2 mutated at the two first amino acids in the tethered ligand 
sequence (rPAR2-Leu
37-Ser38 and rPAR2-Ala
37-38) fails to interact with both β-arrestin-1 and -2 when 
activated by trypsin, resulting in diminished internalization. On the contrary, when activated by the 
PAR2 agonist peptide SLIGRL-NH2, both receptor mutants interacted with both β-arrestins and 
displayed normal internalization compared to wild type PAR2. This shows that the ability to interact 
with β-arrestins also shows some functional selectivity depending on the agonist that activates the 
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receptor, as previously described for intracellular Ca2+ signalling and MAP kinase activation (trypsin 
activates MAP kinase in both mutants, but not intracellular Ca2+ signalling).  
Although the molecular mechanisms that target PAR2 for degradation are largely unknown, 
ubiquitination of some other GPCRs is a prerequisite for degradation 196. PAR2 is shown to be 
extensively monoubiquitinated at multiple sites by the E3 ligase c-Cbl and targeted to lysosomes by an 
Hrs (hepatocyte growth factor-regulated tyrosine kinase substrate)-dependent pathway after activation 
197, 198. Additionally, it is recently shown that endosomal deubiquitinating proteases (DUBs) are key 
regulators of PAR2 down-regulation 
199. For a detailed review of the endocytic trafficking and 
degradation of PARs the readers are referred to Soh et al 2010 66. 
 
Tissue expression of PAR2 
 
A myriad of physiological and pathophysiological events have been attributed to PAR-mediated 
signalling within the last 16 years since their identification. PARs are widely expressed in tissues from 
numerous organ systems and seems to comprise important physiological and pathophysiological roles 
in the cardiovascular and circulatory-, immune- , nervous- , gastrointestinal- , and renal system in 
addition to the respiratory system. Their specific involvement in various processes remain however 
unknown and there are several obstacles to understanding the complete role of PARs 47, 73. First; there 
are a complex interplay within PARs, the multiple PAR activating proteases and disabling proteases, 
protease inhibitors, co-factors or anchoring proteins, and other molecules that may be present in 
different organ systems, and under different pathological conditions. This makes the understanding of 
PAR-mediated events a complex exercise. Secondly; most studies rely on administration of activators 
(proteases or agonist peptides). Although such studies provide information about the potential role of 
PARs, they do not provide direct information about their function in physiology or disease states. 
Proteases are not selective activators of PARs, and agonist peptides are agonists at only very high 
concentrations. Peptides at high concentrations can have biological effects that are unrelated to PAR 
activation. Finally; selective antagonists of PARs are not widely available. In the absence of selective 
activators and antagonists, the best current approach to specifically determine the role of PARs in vivo 
is to study genetically modified animals. Mice have been developed that lack all known PARs 200-205, 
but the use of genetically modified mice is also fraught with problems. Effects of deletion on embryonic 
survival and fertility may impede the breeding of animals for experimentation. These facts have to be 
kept in mind when current knowledge regarding PARs is assessed.  
PAR2 is expressed ubiquitously by barrier cells of a variety of organs (i.e. epithelia and endothelia). 
The epithelial expression of PAR2 is particularly striking and has led authors to suggest that PAR2 may 
be involved in defensive reactions at these barriers 108, 109, 206, 207. To highlight the prevalence and 
multifaceted functions of PAR2 a short summary of the expression and function of this receptor in 
different organ system is given below before a more detailed resumé of the existing information 




PAR2 in the cardiovascular and circulatory system 
PARs are expressed by multiple cells in the cardiovascular and circulatory system, and PAR2 
expression is detected both on endothelial cells 208, 209 and vascular smooth muscle cells 210, 211. 
Activation of endothelial PAR2 (rat/porcine/human) causes vascular relaxation 
76, 212, 213. PAR2 
activation can also cause proliferation of cultured vascular smooth muscle 214, 215 and endothelial cells 
209, and an in vivo murine model shows stimulation of angiogenesis after PAR2 activation 
216. 
Additionally, inflammatory agents (TNFα, IL-1, LPS) and tissue damage is found to up-regulate PAR2 
in the vasculature 217-220. 
 
PAR2 in the immune system 
PAR expression is revealed on many immune cells and the primary response mediated by PARs in 
the immune system appears to be related to chemotaxis and cytokine release from inflammatory cells. 
PAR2 is detected on mast cells 
221, eosinophils 222, monocytes 223, macrophages 223, 224, and 
neutrophils 225-227. 
The function of PAR2 activation in these cells is not always clear, but eosinophil PAR2 activation 
results in degranulation and superoxide production 222, 228. Exposure to mast cell tryptase induces 
eosinophil IL-8 release 229, while stimulation with trypsin and PAR2 agonist peptide triggered shape 
change and release of cysteinyl leukotrienes 228. Neutrophil PAR2 activation causes shape changes 
and enhanced CD11b/CD18 expression 225, and PAR2 agonists is also shown to cause enhanced 
neutrophil motility in 3D collagen gel lattices through up-regulation of cell surface integrins 227. 
 
PAR2 in the nervous system 
The expression of all four PARs has been detected in CNS of rodents 230. PAR2 expression has been 
found on normal human astrocytes and neurons 210, rat spinal cord and isolated dorsal root ganglia 231, 
and guinea pig myenteric 120 and submucosal neurons 232. 
A majority of the research involving PARs in the nervous system deals with PAR1 and PAR2 is to a 
lesser extent investigated. PARs in the central nervous system are shown to influence upon the 
astrocyte morphology and proliferation, and morphology and outgrowth of neurites in nerve cells 47. 
Studies on PAR2 function in the peripheral nervous system have pointed to a role for these receptors 
in neurogenic inflammation 125, hyperalgesia, analgesia 126 and itching 233, as well as playing roles in 
nerve regeneration 234, gastric epithelial ion secretion 235 and mucous secretion function 236, 237.  
 
PAR2 in the gastrointestinal system 
Of all the body systems, the gastrointestinal tract is most exposed to proteases, both from 
physiologically relevant processes such as digestion and from exposure to the bacterial flora of the 
gut. All of the PARs have been found to be expressed in the gastrointestinal tract and PAR activation 
is involved in ion transport, permeability, motility and inflammation 47. PAR2 expression is detected on 
enterocytes 127, epithelial cells 97, smooth muscle cells 76, endothelial cells 238, colonic myocytes 127, 
myofibroblasts 239, and neurons 232. 
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PAR2 in the renal system 
Initial PAR studies showed abundant expression of PAR2 mRNA in the kidney 
71 and further work has 
documented the presence of PARs widely distributed throughout the kidney 202, 240. PAR2 activation 
has been found to cause vasodilatation in a perfused rat kidney model 240, 241 and mediation of 
mesangial cell proliferation (by factor Xa activation) 242. 
 
 
PAR2 in the airways  
 
Distribution of PAR2 
 
PAR expression is detectable in a wide range of airway cells, and evidence so far suggests that PARs 
play critical roles in pulmonary physiology and pathology. Although human PAR2 mRNA was found to 
be highly expressed in cultures of A549 cells (a human lung epithelial cell line) 97, the first evidence 
that PAR2 protein was expressed in the intact lung was provided by D’Andrea and co-workers (1998) a 
few years later 210. PAR2 expression is detected on ciliated and non-ciliated epithelial cells, especially 
at the apical membrane 42, 44, 108, 150, 210, 243, glands 244, smooth muscle cells 108, 210, 245, 246, endothelial 
cells 210, 246, fibroblasts 57, 113, 247, and the mesothelial cells of the pleura 248. In human foetal lung tissue, 
marked PAR2 immunoreactivity is also observed in cuboidal type II-like epithelial cells 
110. 
 
Function of PAR2 
 
As in most other tissues, the physiological agonists of PAR2 in the airways remain to be determined. 
All proteases that are experimentally shown to activate PAR2 are listed in the previous chapter, but a 
vast number of these are exogene proteases and yet others are proteases not encountered in the 
airway tissue. Potential endogen airway PAR2 agonists are mast cell tryptase 
122 and human airway 
trypsin 113. Neutrophil proteases (proteinase 3, cathepsin G, neutrophil elastase) are in numerous 
sources indicated as possible PAR activators in addition to their confirmed role as PAR2 inactivators 
151, 152, but so far PAR2 activation has not been confirmed with certainty.  
An important function of PARs in the respiratory system involves the regulation of airway tone by 
causing either a contraction or relaxation of smooth muscle cells 249. Their involvement has also been 
demonstrated in remodelling of the lung, through promoting secretion of pro-inflammatory and pro-
fibrotic mediator release 250, the production of extra-cellular matrix components and through 
stimulating cell mitogenesis 251. PARs may also regulate the inflammatory response in the airways 
through recruitment of inflammatory cells 109, 249. The effects attributable to PAR2 in these conditions 





PAR2 plays an important role in regulating airway tone with studies showing both protective 
bonchodilatation as well as detrimental bronchoconstriction. Epithelial PAR2 activation in isolated 
bronchi results in relaxation in mice 108, rats 108, 252, guinea pigs 108, and humans 108. Relaxation also 
occurs in isolated mouse and guinea pig trachea and was found to be mediated by prostaniods in 
mice, particularly PGE2 
253-255. As opposed to these reports, activation of PAR2 in isolated human 
bronchi and second order intrapulmonary bronchi from guinea pig leads to constriction following 
administration of PAR2-AP 
246, 255. 
In addition to these diverging results in airway tone collected from tissue preparations, the results from 
in vivo studies in different animal species are also contradictory. In vivo studies in rats show that 
aerosol administration of PAR2-AP inhibits serotonin-induced bronchoconstriction 
108, while in vivo 
studies conducted in mice reports that intranasal administration of PAR2-APs causes 
bronchoconstriction 204. These observations could be due to inter-species differences; however, in vivo 
results originating from the same species (guinea pig) are also inconsistent. Intravenous 
administration of PAR2-AP is shown to inhibit histamine-induced increase in airway resistance by a 
mechanism independent of the release of prostaglandins, nitric oxide or the effect of circulating 
adrenaline 256. In contrast, intravenous and intra-tracheal administration of PAR2-AP causes 
bronchoconstriction, an effect mediated in part by prostanoids that involves the release of tachykinins 
from sensory nerve endings 255. 
The conflicting observations concerning airway tone could be due to a dose-repose relationship 
yielding dissimilar responses according to the administered doses; however, the concentrations of 
peptide agonist used do not diverge much. A possible explanation for this discrepancy is that PAR2 
activation results in relaxation in the main bronchi and the trachea, but causes a contractile response 
in tissues isolated from smaller intrapulmonary bronchi 255. Thus, PAR2 may be protective in the larger 
airways, but activation in the smaller bronchioles may increase airway resistance, an effect that might 
be detrimental in the intact animal as the smaller bronchioles are the principal site of airway resistance 
47, 70. Finally, although the use of agonist peptides in PAR-related research usually yields receptor 
specific results, some of the observed effects of proteases on airway resistance could be independent 
of activation of PAR2. For example, trypsin can evoke contraction of isolated guinea pig bronchus, 




In addition to the regulation of airway tone, PAR2 is shown to be involved in a variety of cellular effects 
like growth and proliferation, migration, secretion of inflammatory mediators, and disruption of cellular 
adhesions; all factors that may contribute to the initiation and progression of -, as well as accompany 
inflammation. 
Activation of PAR2 is shown to induce proliferation of smooth muscle cells 
118, 245, 258, epithelial cells 259, 
and fibroblasts 57, 113. Cellular growth and proliferation may lead to airway remodelling and fibrosis in 
addition to regeneration and reparation of damaged tissues. 
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Activated PAR2 also leads to migration of inflammatory cells into the airway tissue. Berger and co-
workers (1999) have demonstrated increased mast cell infiltration into subepithelial tissue in isolated 
human bronchi following mast cell tryptase stimulation, an effect thought to be acting via PAR2 
260. 
Macrophage and eosinophil infiltration into the airway is also shown to occur following PAR2 activation 
204. Infiltration of inflammatory cells will increase the affected tissues responsiveness to activating 
mediators. In vivo studies in mice show increased airway hyperresponsiveness and inflammatory cell 
infiltration in response to PAR2 agonist administration. Additionally, these effects are shown to be 
lowered if the receptor is lacking as there are observed reduced eosinophil infiltration, reduced airway 
hyperreactivity and reduced IgE levels to ovalbumin in PAR2-deficient mice 
204, 261. On the contrary, 
both Moffatt and co-workers (2002) and De Campo and Henry (2005) found that intranasal delivery of 
PAR2-AP in mice did not cause airway inflammation, but instead inhibited the marked immune cell 
inflammatory response (infiltration of polymorphonuclear leukocytes) triggered by LPS administration 
262 and inhibited the development of eosinophilia and hyperresposiveness following ovalbumin 
challenge 263. 
These diverging results presenting both pro- and anti-inflammatory effects reflect what is found in the 
studies regarding airway tone, where PAR2 in many instances displays a negative contractile effect, 
but in other studies seems to have a protective relaxant effect. However, it is to be noted that these 
conflicting reports used different concentrations of the PAR2-AP for stimulation; the researches that 
report pro-inflammatory effects had stimulations in the µg-scale (160 µg/kg for Schmidlin et al 2002 204 
and around 80 µg/kg for Ebeling et al 2005 261), while the anti-inflammatory effects were observed 
using stimulations in the mg-scale (25 mg/kg for Moffatt et al 2002 262 and De Campo and Henry 2005 
263). The anti-inflammatory effects following PAR2 activation is linked to the secretion of PGE2. As 
concluded by Chignard and Pidard (2006), these diverging results might perhaps be due to differential 
production of PGE2 when PAR2 is activated by high or low peptide concentrations 
264. 
 
Furthermore, PAR2 is shown to be involved in the release of different mediators from cultured airway 
cells. Activation of PAR2 is shown to mediated release of MMP-9 
182, IL-6, IL-8 and PGE2 
42
 from 
human airway epithelial cells (A549, SAEC (small airway epithelial cells)), and macrophage 
inflammatory protein (MIP)-2 from murine mesothelial cells 248. Allergen stimulated airway epithelial 
cells (A549) is shown to release GM-CSF and eotaxin, an effect possibly mediated by PAR2 
149, 243, 
and recent reports have also suggested a role for PAR2 in stimulating cytokine production in cultured 
airway fibroblasts 247.  
Additionally, activation of PAR2 is shown to influence upon the contact that exist between epithelial 
cells, a function that is essential in maintaining the integrity and homeostasis of intact, healthy tissue. 
A report by Winter and co-workers (2006) describes that PAR2 activation interrupts E-cadherin 
adhesion and compromises the airway epithelial barrier that divides the epithelium into functionally 
restricted apical and basolateral domains 265. Furthermore, PAR2 is also suggested to have a role in 
stimulating adhesion molecule expression in cultured airway fibroblasts 247, an effect that might 
influence upon infiltration of neutrophils during an inflammatory response. 
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Contribution to physiological and pathophysiological mechanisms in the 
inflammatory response 
 
The specific physiological functions of PAR2 in the airways and other organ systems are currently a 
topic under investigation. Existing information points to a dual role with both pro- and anti-inflammatory 
effects of receptor activation and the role of PAR2 in pulmonary biology seem to be particularly 
intriguing. The pro- and anti-inflammatory effects caused by receptor activation do not have to be 
mutually exclusive. Inflammation is essentially a protective response intended to eliminate both the 
initial cause of cell injury and the necrotic cells and tissues arising as a consequence of such injury. As 
such, inflammation is also intimately interwoven with protective mechanisms and repair processes. For 
the inflammation to be beneficial it has to be confined to the damaged area and self-limiting. In order 
to accomplish this, protective mechanisms as well as tissue repair processes must be activated and 
the inflammatory response terminated when the injurious stimulus is removed. The possibly dual role 
observed for PAR2 may reflect this complex relationship. Activation of PAR2 by endogenous agonists 
may be a part of the physiological regulation of both pro- and anti-inflammatory effects, while in 
situations where PAR2 is activated by excessive amounts of exogenous proteases this equilibrium 
may be interrupted and the pro-inflammatory qualities becomes more prominent. In addition to the 
frequently discussed effects on inflammation, PAR2 is found to be involved in electrolyte transport 
across airway epithelial cell membranes. The composition of electrolytes may also have impact on 
airway inflammatory processes as imbalances in the secretion/absorption of ions can influence the 
airway surface liquid volume, an important component of the mucociliary clearance machinery.  
 
Inflammation 
Infection or injury to the body results in inflammation. During inflammation and trauma, proteases from 
the coagulation cascade and from inflammatory cells could regulate pulmonary cells by activating 
PARs. There are elevated levels of coagulation proteases 266 and tryptase 267 in bronchoalveolar 
lavage from patients with chronic inflammatory diseases. PAR2 (in addition to PAR1 og PAR4) have 
been implicated in mediating the vascular responses in inflammation like increased leukocyte 
endothelial adherence and rolling, as well as migration of leukocytes from vasculature into inflamed 
tissue. The increased expression of proteinases from inflammatory cells and from activation of the 
coagulation cascade very likely serves as triggers for the PARs in this type of setting 47. 
In vivo studies conducted in rat shows that intraplantar administration of PAR2-AP causes oedema and 
granulocyte infiltration from the vasculature 268. The oedema is found to be dependent on the release 
of neuropeptides from sensory nerves, whereas the extravasation of granulocytes is believed to be 
due to a direct effect of activating PAR2 on endothelial cells. Activation of PAR2 on pleural mesothelial 
cells in mice results in chemokine release and neutrophil recruitment into the pleural cavity, indicating 
that PAR2 plays a role in promoting pleural inflammatory responses 
248. Inflammation is usually 
accompanied by hyperemia. PAR2 agonists are shown to dilate blood vessels in the human arm by 
mechanisms that include nitric oxide and prostaglandins, leading to hyperemia 269.  
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Although PAR2 is found to be expressed on a majority of immune cell types, the function in these cells 
is not always clear. The primary response mediated by PARs in the immune system appears to be 
related to cytokine release from inflammatory cells and chemotaxis. PAR2 activation results in IL-6, IL-
8, and cysteinyl leukotriene release from-, shape changes in- and degranulation of eosinophils 222, 228, 
229. Shape changes and enhanced motility are also observed in neutrophils 225, 227. Furthermore, PAR2 
is shown to be involved in leukocyte chemotactic migration by directing localized actin filament 
severing and membrane protrusions 173. 
Chemokines released from airway cells induces inflammatory cells to leave the bloodstream and enter 
into the surrounding lung tissue. Cultured human airway epithelial cells are shown to secrete IL-8 
following PAR2 activation 
42 and in cultured murine mesothelial cells PAR2 agonist peptide stimulate 
release of macrophage inflammatory protein (MIP)-2 248. Yagi and co-workers (2006) report that 
epithelial PAR2 stimulation enhance neutrophil adhesion to alveolar type II epithelial cells (A549), an 
effect that seems to be mediated by reorganization of the actin cytoskeleton in the epithelial cells 190. 
Recently it has been reported that PAR2 cooperates with toll-like receptors (TLRs). This implies a 
previously under-appreciated role of PARs as an additional level of the innate immune defence, apart 
from classical pattern-recognition receptors 159. Additionally, proteases are shown to induce production 
of thymic stromal lymphopoietin (TSLP) in a human airway epithelial cell line (BEAS-2B) through 
PAR2. By promoting TSLP production in the airways, proteases may facilitate the development and/or 
exacerbation of Th2-type airway inflammation, a process that seems to involve PAR2 
270. 
Chronic inflammation of mucosa is associated with an increased cancer risk and tumorigenesis in 
mucosal tissues is associated with the activity of some proteases, COX-2, and β-catenin 185. Serine 
proteases may participate in inflammation and tumorigenesis through the activation of PAR2. In human 
lung epithelial cells (A549), PAR2 activation is shown to increase COX-2 expression via an ERK 1/2-
mediated activation of the β-catenin/T cell factor-4 and CREB pathways 185. These findings by Wang 
and co-workers (2008) 185 reveal new cellular mechanisms by which serine proteases may participate 




The amount of studies indicating that PAR2 is involved in a vast number of pathological conditions is 
increasing. Although our attention is focused on the pro-inflammatory qualities of PAR2, there is also 
existing information that links the receptor to protective processes. The best evidence for PAR2 being 
involved in normal physiological processes is cytoprotection in the pancreas and upper small intestine 
since these organs are episodically exposed to high concentrations of pancreatic trypsin 206. PAR2 is 
abundantly expressed on epithelia in the pancreatic duct 106 and intestine 104 and its activation leads to 
a range of cytoprotective effects driven largely by release from the epithelia of the secondary mediator 
prostaglandin E2 (PGE2) 
206. A similar PAR2 and prostanoid-dependent cytoprotective system, as seen 
in the gut, might operate in the bronchial epithelia of the airways 108, 206. A number of the effects 
produced by PAR2 activators within the airways may be mediated by PGE2 
271. Although the potential 
involvement of PGE2 in these effects has not fully been determined, PAR2-mediated generation of 
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PGE2 appear to have functional consequences in relation to the production of bronchoprotective 
effects like bronchodilation, inhibition of recruitment and activation of mast cells and eosinophils, as 
well as inhibitory effects on fibroblasts, possibly reducing airway remodelling 271, 272. Airway epithelium 
is shown to release PGE2 following PAR2 activation 
42, but the net effect of this secretion is not 
determined as PGE2 also exhibits pro-inflammatory effects. Depending on the context, PGE2 may 
induce fever, increase vascular permeability and vasodilation, and enhance pain and oedema caused 
by other agents 273 as well as mediating the anti-inflammatory effects previously described. 
 
However, pro- or anti-inflammatory properties, the source of the naturally-occurring enzyme activator 
of airway PAR2 under these possible cytoprotective events need careful consideration. Mast cell 
tryptase (MCT) is known to activate PAR2 
98, 122, although less effectively than trypsin. MCT has been 
reported to be a mitogen for a variety of cells involved in airway wall remodelling 206 and can cause 
airway hyper-responsiveness 55, 260 in isolated bronchi (guinea pig, human). PAR2 is by many thought 
to be the molecular target central to these effects giving it a pro-inflammatory role. It is likely that MCT 
is a genuine PAR2 activator on many airway cells, but some space-distance limitations have been 
commented. Because airway epithelia mostly express PAR2 on their apical surfaces 
108 and the 
population of intraepithelial mast cells is confined to the most basal regions of the airway epithelium 
274, it is difficult to envisage MCT being able to transverse the molecular sieve of tight junctions 
between epithelial cells that separate the airway lumen from the submucosa to activate apically 
restricted PAR2 under normal conditions. In asthmatic patients, on the other hand, the epithelial 
disruption is widespread 275 and MCT can be detected in bronchoalveolar lavage (BAL) fluid 267. 
Though, it might be a possibility that PAR2 is positioned apically in order to detect MCT during 
perturbations of the epithelial barrier and such being a part of the airway cytoprotective system. On the 
other hand, the up-regulation of PAR2 expression detected in asthmatic patients 
44 may also contribute 
to pro-inflammatory events. Until we have knowledge about all physiological activators and target 
signalling pathways of PAR2 it seems to be a difficult exercise to determine the exact effects of 
receptor activation in vivo. 
An alternative to the hypothesis that MCT is the primary PAR2 activator in the airways is tryptic 
enzymes secreted at the apical pole of epithelial cells under “normal” circumstances, like human 
airway trypsin 109, 113. The demarcation between the luminal and subepithelial compartments by tight 
junctions, allows trypsin and MCT to have access to different molecular targets. The widespread 
distribution of PAR2 might signify that this receptor acts as a sensor for a variety of enzymes with 
different idiosyncrasies and distinct extracellular environments, playing different roles in homeostasis 
(pro-inflammatory vs. anti-inflammatory) in each case 109. 
 
Electrolyte transport 
PAR2 is also found to regulate ion transport in mouse and human airway epithelial cell cultures 
121, 276, 
277, a mechanism that may control fluid volume and composition at the airway surface through 
regulation of basal Na+ reabsorption and both basal and stimulated anion secretion 70. PAR2 appear to 
be expressed on both the apical and basolateral sides of the epithelium, however only basolateral 
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stimulation resulted in inhibition of Na+ conductance and stimulation of both luminal Cl- channels and 
basolateral K+ channels 121, 276. A delicate balance between sodium (Na+) absorption and chloride (Cl-) 
secretion is necessary to optimize the volume of airway surface liquid, this in order to promote ciliary 
activity and mucociliary clearance, effectively removing inhaled particles. Stimulation of PAR2 may 
cause accumulation of airway surface liquid, a process that may help to flush noxious stimuli away 
from the affected airways. 
 
PAR2 in mechanisms of airway disease 
 
Proteases and PARs make important contributions to a variety of diseases. First; PARs regulate many 
biological processes that are critical in disease, including coagulation, proliferation and survival, 
inflammation, neurotransmission, and pain. Second; proteases that activate PARs are generated 
during diseases, for example, in trauma, hemostasis, inflammation, and tumor formation. Finally; the 
expression and function of PARs are altered in disease 73. 
Many cell types known to play important roles in both the healthy and diseased airways express 
functional PAR2. Studies in animal models have shown that altering the level of PAR2 expression or 
administering exogenous PAR2 activators can significantly change the course of several airway 
diseases. Furthermore, some respiratory tract diseases have been associated with altered levels of 
PAR2 expression and function 
271. PAR2 is generally found to be up regulated during inflammation 
220, 
278, and lung inflammation induced by lipopolysaccharide 279 or influenza A virus 280 is also associated 
with increased expression of PAR2. Levels of immunoreactive PAR2 staining in the epithelium of 
bronchial biopsy specimens obtained from asthmatic subjects were significantly higher than non-
asthmatic subjects 44. PAR2 is also found to be highly expressed in airway epithelium of preterm 
infants who died of prolonged respiratory distress syndrome or of bronchopulmonary dysplasia. The 
level of PAR2 expression tended to increase with progression of respiratory distress syndrome toward 
bronchopulmonary dysplasia 110.  
Not all pulmonary insults are associated with increased PAR2 expression. Smoking does not appear to 
affect levels of PAR2 as expression was found to be similar in the central airways of smokers and non-
smokers (bronchial smooth muscle, epithelium, glands, vascular endothelium, vascular smooth 
muscle, alveolar macrophages) 224, 244. However, when smokers were divided according to the 
presence of symptoms of chronic bronchitis or chronic airflow limitation (COPD), PAR2 expression was 
increased in vascular smooth muscle of smoking patients with bronchitis compared to smoking 
patients with COPD 244. 
 
Neutrophil derived proteases such as elastase and cathepsin G are capable of disarming PAR2 most 
likely by proteolysis of the extracellular domain downstream from the trypsin cleavage/activation site 
151. Elastase (an elastolytic metalloprotease) from Pseudomoas aeruginosa, a major pathogen in 
cystic fibrosis, is also shown to disable PAR2 in respiratory epithelial cells. This might alter the host’s 
innate defence mechanisms and respiratory functions, thus contributing to the disease pathology in 
cystic fibrosis 153. Using a murine model of acute P. aeruginosa pneumonia, Moraes and co-workers 
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(2008) have examined differences in the pulmonary inflammatory response between wild-type and 
PAR2 (-/-) mice. Compared with wild-type mice, PAR2(-/-) mice displayed more severe lung 
inflammation and injury in response to P. aeruginosa infection as indicated by higher bronchoalveolar 
lavage (BAL) fluid neutrophil numbers, protein concentration, and TNFα levels. They conclude that 
genetic deletion of PAR2 is associated with decreased clearance of P. aeruginosa, and the data 
suggest that a deficiency in IFNγ production and impaired bacterial phagocytosis are two potential 
mechanisms responsible for this defect 281. 
 
 
There has been considerable interest in the role of tryptase in airway inflammation and asthma. 
Hyperplasia of smooth muscle contributes to remodelling of the airways that accompanies asthma, 
and tryptase induces proliferation of airway smooth muscle cells, fibroblasts, and epithelial cells 259, 282, 
283. Tryptase also induces hyperresponsiveness in human isolated bronchi 260. Similar effects on 
cellular proliferation and airway hyperresponsiveness is produced by PAR2 agonist peptides 
57, 245.  
A key step in activation of human airway smooth muscle cells is an increase in free intercellular Ca2+ 
concentration. Tryptase induces an increase in intracellular Ca2+ that is significantly inhibited by the 
use of siRNA against PAR2 
117, indicating that airway hyperresponsiveness in fact is mediated by 
tryptase activation of PAR2. Animal studies have shown that selective inhibition of tryptase and serine 
protease inhibition blocks airway inflammation in mouse asthma models, reducing total cells, 
eosinophils and lymphocytes in BAL fluid, airway tissue eosinophilia, goblet cell hyperplasia, mucus 
secretion, and peribroncheal edema in addition to an inhibition of IL-4, IL-13, and eotaxin release in 
BAL fluid 284, 285. These findings suggest that increased serine protease activity in the airways is 
involved in the development of allergic eosinophilic inflammation and epithelial remodelling in 
bronchial asthma, effects possibly mediated by PAR2 activation. Furthermore, ovalbumin-induced 
infiltration of eosinophils and increased eotaxin content is shown to be abrogated in BAL fluid from 
PAR2 (-/-) mice, indicating that activation of PAR2 might be essential in the production of eotaxin and 
consequential allergic inflammation in the airways 286.  
 
An imbalance between protease and antiprotease activity in the lung is proposed as the major 
mechanism resulting in emphysema 287. Neutrophil elastase is more than a matrix-degrading enzyme, 
and is considered to have potential multiple roles in the pathogenesis of both emphysema and lung 
fibrosis 288. α1-antitrypsin is the natural inhibitor of neutrophil elastase and low levels of α1-antitrypsin is 
associated with COPD 289, asthma 290, and bronchiectasis 291. Although it is not established that PAR2 
is involved in the pathological mechanisms caused by neutrophil elastase, it is a serine protease with 
the potential of being a PAR2 activator in addition to the demonstrated capacity to inactivate PAR2 
151. 
A deficiency in the natural protease inhibitor would influence on the balance between protease and 
antiprotease resulting in a cellular environment displaying increased protease activity possibly leading 





The observation that inflammation is diminished in PAR-deficient animals suggests that PAR 
antagonists and protease inhibitors may be useful anti-inflammatory agents 73. Developing PAR2 
antagonists have presented a great challenge with very limited success so far. Largely because of (1) 
the difficulty in synthesizing serine protease inhibitors that are enzyme selective and (2) the ability of 
several serine proteases to activate PARs 2 and 4, the receptor-activating proteases themselves do not 
appear to be attractive therapeutic targets for blocking the activation of these two PARs 47. 
The most promising results so far is with compounds that targets the receptor; PAR2 antagonists. 
Some success has been achieved with antagonists based on modified PAR2 tethered ligand peptides 
(FSLLRY-NH2, LSIGRL-NH2), but the potency are too low to be considered for general systemic use 
292. These peptides are able to inhibit trypsin activation of PAR2 through possible interactions with the 
tethered ligand docking site, but are of limited use to block activation of PAR2 by PAR agonist 
peptides. The peptide, LIGK-NH2 is found to block both trypsin and PAR2 agonist peptide activation of 
PAR2 and a peptidomimetic based on this peptide sequence, ENMD-1068 (N1-3-methylbutyryl-N4-6-
amino-hexanoyl-piperazine), has proved of use in studies done in vivo, despite a very low potency 293. 
Although ENMD-1068 can serve as a “lead” compound, the synthesis of high potency orally available 
PAR2 antagonists is a goal yet to be reached. 
PAR2-targeted antibodies (polyclonal B5, monoclonal SAM11) and PAR2-targeted siRNAs may prove 
of therapeutic value, but the methods is not sufficiently developed to be considered for therapeutic use 
as of yet 293.  
Although the PAR-activating proteases are challenging therapeutic targets, protease inhibition by 
protease inhibitors in a restricted environment may have value. The serine protease-dependent, 
PAR2 mediated inflammation caused by Citrobacter rodentium in a murine model of colitis can be 
attenuated by the oral administration of the soya trypsin inhibitor 294. Additionally, the systemic 
administration of protease inhibitors in a murine model of joint inflammation is able to diminish joint 
swelling significantly 293. 
The fact that different proteases can activate the same PAR to elicit distinct signalling responses 
suggests that different drugs could be developed to target PAR signalling selectively. In order to 
design drugs to meet these expectations we must achieve more knowledge about the signalling and 
cell type-specific responses elicited by different proteases, as well as receptor interactions and 





Selected signalling molecules 
 
Cytokines 
A hallmark of inflammation is the recruitment of neutrophils from the blood to the injured tissue, a 
process directed by chemotactic cytokines called chemokines. About 40 human chemokines are 
known today with IL-8 as the founding member of this superfamily 295, 296. Effects from IL-8 secretion 
involve three main changes in neutrophils; (1) shape changes and directional migration, (2) exocytosis 
of storage proteins, and (3) the respiratory burst 295. One of the most remarkable properties of IL-8 is 
the variation of its expression level. Normally, IL-8 protein is barely secreted from non-induced cells, 
but its production is rapidly induced by a wide range of stimuli encompassing proinflammatory 
cytokines like tumor necrosis factor (TNF) or IL-1 297, 298, bacterial 299, 300 or viral products 301, 302 and 
cellular stress 303-306. IL-8 can be synthesized by a variety of cell types including human pulmonary 
epithelial cells (A549) 186.  
 
Mitogen activated protein kinases 
Protein kinases participate in protein phosphorylation cycles where the kinase covalently links a 
phosphate group to the substrate generating a phosphorylated target protein 64. The members of the 
mitogen activated protein (MAP) kinase family are protein serine/threonine kinases controlling key 
cellular functions including gene transcription, protein synthesis, proliferation, differentiation, migration, 
embryogenesis, and apoptosis. These kinases are shown to participate in a diversity of physiological 
and pathological conditions like embryonic development, metabolism, learning, innate and acquired 
immunity, chronic inflammation, heart disease, diabetes mellitus, and cancer 307, 308. 
Four MAP kinase cascades have so far been defined in mammals; the extracellular signal-regulated 
kinase (ERK 1/2), the p38 kinases, the c-Jun N-terminal kinases (JNK 1/2/3), and the ERK5/BMK (BIG 
MAPK) 309, 310. These different cascades respond to distinct extracellular stimuli. Activation of two of 
these cascades following trypsin exposure is explored in this work; 1) The extracellular signal-
regulated kinase regulates differentiation, proliferation, and meiosis in response to mitogens like 
growth factors, cytokines, and phorbolesters. 2) The p38 kinases are involved in immunity and are 
activated by chemical and physical stresses like UV irradiation, bacterial lipopolysaccharides, 
ischemia, cytokines, osmotic shock, and heat shock. The two latter cascades (JNK 1/2/3 and 
ERK5/BMK) are not explored in the present study. 
 
Transcription factors 
NF-κB is a collective term referring to dimeric transcription factors that belong to the Rel family and are 
regulated via shuttling from the cytoplasm to the nucleus in response to cell stimulation 311. Inactive 
NF-κB is present in the cytoplasm of all cells; only when it is activated and translocated to the nucleus 
is the activating sequence of events generated. Mammals express five Rel (NF-κB) proteins that 
belong to two classes. The first class includes RelA (p65), RelB, and c-Rel, proteins that are 
synthesized as mature products and do not require proteolytic processing. The members of the 
second group is synthesized as large precursors, p105 (NF-κB1) and p100 (NF-κB2), that require 
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proteolytic processing to produce the mature p50 and p52 NF-κB proteins. NF-κB dimers containing 
RelA or c-Rel are held in the cytoplasm through interaction with specific inhibitors, the IκBs. These 
inhibitory proteins undergo rapid ubiquitin-dependent degradation after exposure to a variety of 
agonists, which activate the IκB kinase (IKK) complex 312. Activated NF-κB dimers then translocate to 
the nucleus and bind to their specific base pair site and regulate the expression of over 200 immune, 
growth, and inflammation genes including IL-8 gene expression 313. This pathway of NF-κB activation 
is called the classical (canonical) pathway, see fig 3. The second major pathway for NF-κB 
activation; the alternative pathway, results in specific activation of p52/RelB heterodimers. The 
alternative pathway is not directly involved in innate immunity and inflammation, but is required for the 






Figure 3  
Classical NF-κB pathway 
The classical NF-κB pathway is activated by a variety of inflammatory signals, resulting in coordinate expression 
of multiple inflammatory and innate immune genes. The proinflammatory cytokines IL-1β and TNF-α activate NF-
κB, and their expression is induced in response to NF-κB activation, thus forming an amplifying feed forward loop. 
(COX-2) cyclooxygenase 2, (GM-CSF) granulocyte–macrophage-colony-stimulating factor, (ICAM-1) intercellular 
adhesion molecule 1, (IKK) IκB kinase, (IL-1β) interleukin-1β, (iNOS) inducible nitric oxide synthase, (MCP-1) 
monocyte chemotactic protein-1, (MIP-1α) macrophage inflammatory protein-1α, (PLA2) phospholipase 2, (TLRs) 
Toll-like receptors, (TNF-α) tumor necrosis factor α, (VCAM-1) vascular cell adhesion molecule-1. 
Adapted from Bonizzi and Karin (2004), Trends Immunol 25: pp 280 – 288 314 
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Aims of the presented study 
 
The aim of this study was to increase the understanding of serine proteases, PAR2 and their 
respective significance in airway reactivity towards fish (salmon [Salmo salar], sardine [Sardinops 
melanostictus]) and crustaceans (king crab [Paralithodes camtschaticus]). We desired to achieve new 
knowledge about serine proteases originating from seafood and their ability to contribute to 
inflammatory reactions in human airways with emphasis on epithelial tissue. In order to illustrate our 
aim we set out to; 
 
(1) Investigate whether trypsin from salmon can initiate inflammation in human airways by 
activating PAR2 and find out which intracellular signalling systems are involved.  
 
(2) Determine if trypsins from other fish species behave similar to salmon trypsin with respect 
to PAR2 activation and secretion of inflammatory mediators from airway epithelial cells. 
 
(3) Establish if king crab trypsin display similar capacity of activating PAR2 as the fish 
trypsins, and if not, identify alterations in PAR2 activating capacity or PAR2 coupled 
intracellular signalling pathways that might reflect prospective differences. 
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Summary of papers 
 
Paper I 
Bang B, Larsen M, Larsen AK, Aasmoe L. (2009). Proteases from salmon stimulate IL-8 in airway 
epithelial cells. J Toxicol Environ Health A. 72 (9): pp 571 – 573  
 
Bacterial derived endotoxin has often been regarded as the most important exposure agent linked to 
non-allergic airway inflammation in work environments with sources of biological exposures. However, 
there is now increasing awareness of the role of exogenous proteases and activation of PAR2 in 
airway inflammation induced by biological agents. In this paper we have studied the ability of salmon 
tissue extracts from stomach, pyloric ceca, and skin mucus to stimulate IL-8 production in human 
airway epithelial cells. A549 cells were stimulated with various concentrations of fish tissue extracts for 
6 hours before the amount of secreted IL-8 in the supernatant was determined. The role of serine 
protease enzymes and endotoxin in the tissue samples were investigated by the use of inhibitors. We 
show a concentration-dependent increase in IL-8 secretion after stimulation with the salmon tissue 
extracts, an effect most likely due to serine proteases in the tissue samples as the IL-8 stimulating 
effect was inhibited by serine protease inhibitors but not by endotoxin inhibitors. Tissue extract derived 
from the pyloric ceca was most potent in capacity of inducing an IL-8 response in the cell based 
assays and also displayed the highest trypsin-like activity determined by the hydrolyzation of DL- 
BAPNA. Regarding the high content of pancreatic enzymes in this specialized structure with trypsin 
being the most important, these findings were not unexpected. In conclusion, the data in this paper 
demonstrate that fish tissues contain inflammatory potential linked to serine protease activity. 
 
Paper II 
Larsen AK, Seternes OM, Larsen M, Aasmoe L, Bang B. (2008). Salmon trypsin stimulates the 
expression of interleukin-8 via protease-activated receptor-2. Toxicol Appl Pharmacol 230 (3): pp 276 
– 282   
 
In our second paper we focus on salmon trypsin as an activator of inflammatory responses in airway 
epithelial cells in vitro. Unpublished results from our group have revealed that workers in the salmon 
industry are exposed to enzyme-containing aerosols generated during industrial processing of the fish. 
Based on the fact that tissue extracts from fish exhibit an inflammatory potential that can be linked to 
serine protease activity in addition to the knowledge that serine proteases like trypsin are highly active 
mediators with numerous biological functions, we wanted to investigate the capacity of salmon trypsin 
to initiate an inflammatory response in human airway epithelial cells. The stimulation of nuclear factor-
kappa B (NF-κB) and interleukin (IL)-8 and the role of PAR2 in this inflammatory signal mediation were 
investigated. Exposure of A549 cells to purified trypsin isolated from salmon (Salmo salar) yielded a 
concentration-dependent increase in the secretion of IL-8. By the use of siRNA to knock down the 
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endogenous expression of PAR2 in human airway epithelial cells, we show that the increased 
secretion of IL-8 following trypsin stimulation was mediated by activation of PAR2. Additionally, this 
paper demonstrates that PAR2 activation by salmon trypsin is coupled to induction of NF-κB-mediated 
transcription in a PAR2 transfected HeLa model. The results presented in this paper suggest that 
salmon trypsin, by activation of PAR2, might influence upon inflammation processes in the airways if 
inhaled in sufficient amounts.  
 
Paper III 
Larsen AK, Kristiansen K, Seternes OM, Bang B. Molecular modelling of trypsin from the king crab 
(Paralithodes camtschaticus). Manuscript – short communication. 
 
Molecular size, conformation and electrostatic potential are all factors that influence on a molecule’s 
ability to bind and interact with signalling partners. Small chemical changes can inactivate the agonist-
molecule, as the receptor may fail to bind the altered form or bind it less efficiently. The nature of the 
interaction between two signalling partners will influence upon downstream signalling pathways 
following molecular binding and receptor activation/inactivation. During purification of several trypsins 
from fish and king crab we observed that king crab trypsin bound stronger to the anionic column in the 
fast protein liquid chromatography (FPLC) compared to the other fish trypsins we purified. In paper III 
we show by molecular modelling techniques that king crab trypsin displays a more negatively charged 
surface compared to salmon and bovine trypsins. In addition, we identify 3 positions located near the 
substrate binding pocket at which a divergence in amino acid charge in the king crab trypsin molecule 
may influence upon the binding of substrate to PAR2. The king crab trypsin is also shown to be a 
slightly bigger molecule compared to salmon and sardine trypsins. Despite the structural variation, no 
significant differences were found in enzymatic activity between bovine, salmon, sardine, and king 
crab trypsins measured by their ability to hydrolyzate a chromogenic substrate (DL-BAPNA). This 
paper presents preliminary results indicating that differences in electrostatic charge in residues at key 
interacting positions may result in altered binding capacity of the agonist in question, and that 
electrostatic interactions can be of importance in binding, cleavage and subsequent activation of 
PAR2. Still, more extensive molecular modelling studies and cell based assays are necessary in order 
to identify essential residues in the king crab trypsin and how their interaction with binding residues in 
PAR2 might influence upon receptor activation and possible functional selectivity. 
 
Paper IV 
Larsen AK, Seternes OM, Larsen M, Kishimura H, Rudeskaya G, Bang B. Purified sardine and king 
crab trypsin stimulate IL-8 secretion and NF-κB activation, at least partly, via PAR2, but displays 
individual differences in transformation of the NF-κB-signal. Manuscript. 
 
Respiratory symptoms are present in workers processing a great variety of seafood, including the 
salmon, sardine, and king crab industry. Knowing that salmon trypsin is able to induce secretion of IL-
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8 from airway epithelial cells by activating PAR2, we wished to explore if purified trypsins from king 
crab (Paralithodes camtschaticus) and sardine (Sardinops melanostictus) could induce similar effects 
in cell stimulation assays. In addition, research indicate that different types of seafood seem to display 
dissimilar irritant/allergic potencies and a higher prevalence of occupational airway symptoms is 
associated with exposure to aerosols from arthropods (crustaceans) than with bony fish and molluscs 
6. This knowledge inspired us to investigate if we could detect differences in intracellular signalling 
pathways coupled to IL-8 in human airway epithelial cells following stimulation with king crab and 
sardine trypsins. Paper IV shows that both sardine and king crab trypsin are able to induce secretion 
of the pro-inflammatory cytokine IL-8 from cultured human airway epithelial cells (A549) as previously 
shown for purified salmon trypsin. Both trypsins tested (sardine and king crab) generate DNA-binding 
of activated NF-κB, but displays individual differences in transformation of the NF-κB signal. High 
enzyme concentrations of king crab trypsin yields high levels of NF-κB that does not translate into 
increased secretion of IL-8 as opposed to salmon and sardine trypsins where the NF-κB levels 
correlate with the secreted amounts of IL-8 in all enzyme concentrations applied. However, siRNA 
results indicate that both the increased secretion of IL-8 and the generation of activated NF- κB 
following sardine and king crab trypsin stimulation is mediated, at lest partly, by activation of PAR2. 
In an attempt to reveal possible differences in the PAR2 activating potential between the trypsins 
investigated, we further explored the contribution of MEK/ERK, p38 and NF-κB to the secretion of IL-8 
following stimulation with purified sardine and king crab trypsins by the use of specific inhibitors.  
The results from the inhibition assays indicate that MEK/ERK and NF-κB are both required for purified 
sardine and king crab trypsin-induced secretion of IL-8 but via separate pathways, while p38 may 
influence upon activation, nuclear translocation and/or DNA binding of activated NF-κB. Our inhibitor 
assays revealed no significant differences between purified sardine and king crab trypsin that might 
explain the observed discrepancy between NF-κB generation and subsequent IL-8 secretion in the 
upper concentration range of king crab trypsin  
The differences in IL-8 and NF-κB dose-response relationships indicate that small structural variations 
in agonists may lead to differences in receptor activation and subsequent intracellular signalling. 
Future research focusing on possible biased signalling based on molecular structure, charge, and 








In the presented work we wished to investigate if trypsins from seafood were able to induce 
inflammatory reactions in human airways by the use of techniques based on molecular biology. We 
chose to develop a majority of our assays using the A549 cell line. This line was initiated in 1972 
through explant culture of lung carcinomatous tissue from a 58-year-old Caucasian male 315. Further 
studies revealed that the cell line has properties of type II alveolar epithelial cells 316. The A549 cell 
line is well known and widely used. Additionally it is shown to endogenously express PAR2, the 
receptor of our interest 97. Being an immortalized cell line it is fairly easy to work with and displayed 
good transfection efficiency. The latter of particular interest for us as we wanted to develop an assay 
based on receptor knockdown by the use of small inhibitory RNA (siRNA) to verify that our observed 
results in fact were attributable to PAR2 activation. In the final half of this work we also utilized an A549 
cell line stably transfected with a NF-κB-luc element giving us the chance to measure activated NF-κB 
directly without prior transfection of the NF-κB-luc reporter vector. This is an advantage as the protein 
expression in transiently transfected cells may vary more between assays. Our siRNA transfection 
protocol was prepared based on the wild type A549 cell line where a combination of three different 
pre-designed siRNAs targeting the PAR2 gene were shown to reduce the expression of PAR2 with 
91% compared to cells receiving the negative control siRNA. However, follow up studies revealed that 
the A549NF-κB-luc cell line showed inferior transfection efficiency with a 54 – 72% reduction in PAR2 
expression when subjected to the same transfection protocol. This has to be kept in mind when 
comparing the results from paper II and the preliminary results in the manuscript of paper IV. The 
siRNA protocol for the A549NF-κB-luc+ strain is presently under optimization and the assays involving 
PAR2 knockdown will be repeated before manuscript IV is submitted.  
A great proportion of the knowledge regarding signal transduction originates from work involving 
immortalized cell lines. Even though the A549 cell line is frequently used in models investigating 
airway epithelial effects it has to be remembered that it is derived from a malignant tumor and 
therefore may possess differences in cellular signal transduction compared to physiologically normal 
cells.  
 
The A549 cell line is derived from epithelial cells originating from the lower parts of the airways 
(alveolar epithelial cells). Because the observed airway symptoms in fish industry workers were from 
both upper and lower parts of the airways, we originally wanted to investigate if the trypsins were able 
to induce cytokine release from epithelial cells derived from the upper part of the airways as well. In 
order to confirm that the effects observed in the immortalized A549 cell line could be applicable to 
more physiological conditions, as far as can be expected using experiments involving cultured cells, 
we wanted this additional cell line to be of primary origin. We set out to use HNEPC, a primary human 
epithelial cell line derived from the nose, but by the use of real time PCR, this cell line were found to 
express only low amounts of endogenous PAR2. Primary epithelial cell cultures derived from turbinate 
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mucosa is shown to express functionally active PAR2 
317 while epithelial cells from nasal polyps are 
found not to express PAR2 mRNA without prior stimulation 
318. Time limitations did not allow us to 
investigate the approach of establishing tissue sample derived cell cultures. Hence, the possible 
effects of seafood-derived trypsins on human primary nasal epithelial tissue are not included in this 
study. 
 
The HeLa cell line (human epithelial cervical cancer cell line) was chosen for the assays involving 
DNA transfection and recombinant PAR2 receptor expression because this cell line is previously 
shown not to express endogenous PAR2 
1, 97, 319. This allows us to isolate observed effects to PAR2 as 
they will disappear in the wild type cells that are only transfected with control DNA. The use of HeLa 
cells were not chosen for the assays involving IL-8 measurements as they displayed a very high 
background level of IL-8 in non-stimulated cells. 
 
Indicators of inflammation  
 
Inflammation is a condition that involves numerous mediators and signalling pathways in different cell 
types and tissues. In the presented work we use some of these mediators as indicators of the potency 
to cause secretion of inflammatory mediators from cultured airway epithelial cells by the examined 
substances. Both the cytokine IL-8 and the transcription factor NF-κB are mediators that are closely 
linked to inflammation and they are additionally shown to be generated following PAR2 activation 
42, 178, 
182. IL-8 was chosen as an indicator of non-allergic inflammation in our cell stimulation assays. 
Although several cytokines may contribute to the initiation and progression of inflammation they were 
not included, as we merely chose IL-8 as an indicator and not set out to investigate the complete 
spectra of effects induced by seafood trypsins. We measured the secreted levels of IL-8 by ELISA as 
opposed to measurements of intracellular IL-8 levels or mRNA using other techniques, because the 
cytokines have to be secreted in order to exert their effects in promoting inflammation. 
Additionally, we chose to investigate the possible connection between PAR2 activation and DNA-
binding of the transcription factor nuclear factor-κB (NF-κB). NF- κB transcription factors and the 
signalling pathways that activate them are central coordinators of innate and adaptive immune 
responses 320. NF-κB is shown to be essential for induction of IL-8 transcription 186-189 and is 
additionally a transcription factor known to regulate a vast array of genes involved in inflammation 313, 
314. NF-κB was originally selected as an indicator of inflammation in addition to IL-8, giving us a 
stronger connection between the trypsins of interest and their ability to cause inflammation in cultured 
human airway cells. As the work progressed we observed differences in the trypsins with regards to 
their ability to activate NF-κB. Knowing that the transcription factors AP-1 and NF-IL6 are shown to be 
essential for maximal IL-8 expression it may have been of interest to investigate the influence of PAR2 
activation by trypsins upon the activation of these as well, but because of time limitations this will be 




Occupational allergic reactions to seafood can among others manifest as rhinitis, conjunctivitis, and 
asthma 6, but few studies show a clear correlation between symptoms and increased levels of specific 
IgE towards fish. The lack of a strong IgE association implies that other mechanisms may be of 
importance in trigging the observed airway symptoms. Environmental proteases appear to be 
important in the pathogenesis of airway inflammation under certain conditions and their effects are to a 
large extent thought to be mediated by interactions with PARs. Exogenous serine proteases are 
shown to induce production and release of cytokines from airway epithelial cells, a process often 
shown to be mediated by PAR2 activation. Some cytokines are contributing factors that amplify IgE-
mediated inflammation 36, but environmental factors may also stimulate the production of cytokines in 
a non-IgE mediated process. Prior to this work, it has not been established that fish-derived serine 
proteases (trypsins) are capable of activating PAR2 as reported for mammalian trypsins and other 
exogenous serine proteases 38, 39, 41, 47, 70, 73, 136, 137, 139, 141-144, 147, 148, 150.  
 
IL-8 secretion by activation of PAR2 by seafood trypsins  
 
At the start of this work it was known that a wide range of proteases was able to induce production and 
release of IL-8 from airway cells 33-35, 37, 147, 148, 321, 322, an effect often shown to be mediated by 
activation of PAR2. Knowing that PAR2 is considered important for airway inflammation, we set out to 
explore if proteases from salmon could provoke secretion of IL-8 from A549 cells (human airway 
epithelial cells) and if purified salmon trypsin could activate PAR2 as reported for mammalian trypsins.  
 
In paper I we show that crude tissue extracts (pyloric caeca, stomach, skin mucus) from salmon are 
able to cause a concentration-dependent rise in IL-8 secretion from A549 cells. The majority of this 
increased secretion is believed to be caused by serine proteases as the use of serine protease 
inhibitors strongly attenuated the IL-8 levels. Other proteases may be involved as a protease inhibitor 
cocktail exhibited a more pronounced reduction of the IL-8 secretion compared to specific serine 
protease inhibitors alone. Fish skin/mucus and gastrointestinal tract are expected to contain Gram-
negative bacteria as part of the normal bacterial flora. Lipopolysaccharides (LPS) from the cell wall of 
Gram-negative bacteria are shown to be a potent inducer of IL-8 production from human airway 
epithelial cells 161, 179, 323, an effect most probably mediated by interactions with Toll-like receptors 324. 
The use of Polymyxin B (an inhibitor of LPS) did not influence upon the secreted IL-8 levels, giving us 
a strong indication that the increased IL-8 secretion was not due to endotoxins in the tissue extracts. 
The highest potency to cause increased IL-8 secretion were observed following stimulation with tissue 
extracts from pyloric caeca (part of the fish gut consisting of numerous blind sacs embedded in 
pancreatic tissue), a result to be expected as the intestines and particularly the pancreatic tissue 
contain large amounts of enzymes, with trypsin being the most important 325.  
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In paper II we confirm that purified salmon trypsin is able to induce secretion of IL-8 from human 
airway epithelial cells (A549) in a concentration-dependent manner. Secretion of IL-8 following trypsin 
stimulation in A549 is previously shown 42, 326. Although these studies have demonstrated increased 
IL-8 secretion in response to stimulation with trypsin and PAR2 agonist peptide, a firm correlation 
between cytokine secretion and trypsin-induced PAR2 activation in this cell type has not been 
established. By the use of siRNA we were able to give direct evidence that the observed secretion of 
IL-8 following salmon trypsin stimulation is mediated by activation of PAR2. The amount of secreted IL-
8 was reduced with 70 – 85% in PAR2 knockdown cells, leaving a slightly increased residue level in 
PAR2 peptide agonist and salmon trypsin treated cells compared to untreated cells. 
The fact that an observed effect (here; increased levels of IL-8) is abolished when the component 
expected to mediate the effect (here; PAR2) is removed by siRNA is a strong indication of the 
components participation. So, if PAR2 is responsible for the increased levels of IL-8 following purified 
salmon trypsin stimulation, why do we detect a slightly increased IL-8 level in the non-PAR2 
expressing A549 cells that have received siRNA to knock down the receptor? This may be due to the 
fact that siRNA treatment of the A549 cells resulted in a 91% knockdown of the receptor, still leaving 
9% PAR2 mRNA to be translated into functionally receptor protein. There might also be a possibility of 
purified salmon trypsin activating other signalling pathways leading to increased IL-8 secretion. 
Activation of PAR1 and PAR4 are, in addition to PAR2, both shown to induce secretion of IL-8 in human 
airway epithelial cells 42. Trypsin is previously shown to activate PAR1 in addition to PAR2, although in 
higher enzyme concentrations 63, 327 used in our cell based assays (40 nM versus 20 nM at the most in 
our assays). This makes us believe that the contribution of directly activated PAR1 to the observed 
amounts of secreted IL-8 following sardine trypsin stimulation is minor, if at all present. 
The PAR2 agonist peptide, SLIGRL-NH2, has been used as a positive control for PAR2 mediated 
effects in most of our assays. As observed for the salmon trypsin, PAR2 agonist peptide stimulation 
yielded a slightly increased IL-8 level in PAR2 knockdown cells. This increased residue level could be 
due to unspecific effects of the agonist peptide yielding IL-8 secretion as well. The PAR2 agonist 
peptide we used (SLIGRL-NH2) is shown to be specific for PAR2 
328, but PAR agonist peptides are 
functionally agonists at relatively high peptide concentrations (25 µM) and there is a possibility that 
these peptides might influence on receptors and signalling pathways besides PAR2 
47. These 
unspecific peptide effects can be controlled for by the use of inactive scrambled peptides. In our 
assays the inactive peptide LRGILS-NH2 gave no secretion of IL-8, indicating that the increased 
residue level in PAR2 knockdown cells following PAR2 agonist peptide stimulation is not due to 
unspecific effects, but most likely is attributable to incomplete PAR2 silencing. 
 
In paper IV we corroborate that purified trypsins from sardine and king crab are able to induce 
increased IL-8 secretion from A549 cells as observed for crude salmon tissue extracts and purified 
salmon trypsin. The IL-8 secretion following stimulation with these trypsins is also concentration-
dependent, but while purified sardine trypsin follows salmon trypsin with respect to the enzymatic 
concentrations yielding maximal IL-8 secretion, the purified trypsin from king crab stimulates maximal 
IL-8 secretion in a much lower concentration range. When measuring the enzymatic activity in vitro 
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using DL-BAPNA as a substrate there is no observed differences in the enzymatic activity of salmon, 
sardine, or king crab trypsin calculated as Units/µg protein that could explain this divergence.  
Knockdown of PAR2 reduced the secreted amount of IL-8 following stimulation with PAR2 agonist 
peptide, sardine, and king crab trypsin, but not as pronounced as observed following salmon trypsin 
stimulation. We also observe that the reduction following PAR2 agonist peptide stimulation is stronger 
(52%) than for the sardine and king crab stimulated cells (34% at the most). This in contrast to our 
finding in paper II where the reduction following PAR2 agonist peptide and salmon trypsin stimulation 
in PAR2 knockdown cells were nearly at the same level. There is a possibility that the purified sardine/ 
king crab trypsins activate other receptors leading to increased secretion of IL-8 in addition to the 
PAR2 response, explaining the observed dissimilarity in agonist and trypsin-stimulated PAR2 
knockdown cells. However, the reduced decline in IL-8 secretion from PAR2 knockdown cells after 
stimulation with sardine and king crab trypsins compared to salmon trypsin (34% at the most for 
sardine and 31% at the most for king crab versus 82% at the most for salmon trypsin) is most likely 
due to the A549NF-κB-luc+ cell type and its transfection capability compared to the wild-type A549 cell 
line used in paper II. Follow up studies with real-time PCR showed that siRNA targeting PAR2 reduces 
the expression of the receptor mRNA levels with 54 – 72% in the A549NF-κB-luc+ cells as compared 
to 91% in the wild type A549 cell line. The probability for this scenario is strengthened by the fact that 
the level of IL-8 also declines less following PAR2 agonist peptide stimulation in the A549NF-κB-luc+ 
cell type, from 85% reduced secretion in PAR2 knockdown A549 wild type cells to 52% in A549NF-κB-
luc+ cells.  
Additionally, in paper II the results from PAR2 knockdown cells were compared to non-transfected cells 
as initial investigative real-time PCR assays showed no reduction in PAR2 expression following 
transfection with negative control siRNA. Subsequent assays conducted prior to paper IV showed a 
reduced secretion of IL-8 (26 – 30%) in mock-transfected cells receiving the negative control siRNA, a 
result probably due to unspecific cellular effects following the transfection routine. This resulted in our 
incorporation of the negative control siRNA in the assays that are described in paper IV, yielding minor 
reductions when comparing the PAR2 knockdown cells to mock-transfected rather than non-
transfected. Independent of comparisons made between the papers the level of IL-8 secreted from 
agonist treated PAR2 knockdown A549NF-κB-luc+ cells was significantly reduced, showing that 
activation of PAR2 provide a major contribution to the increased secretion of IL-8. Even though the 
results from the trypsin stimulated cells did not reach significance, the reduction observed in PAR2 
knockdown cells is most likely due to PAR2 involvement. Besides rejecting a connection between 
compared groups/events, lack of significance can also be contributed to the number of observations 
included in the calculation. Smaller differences between groups would need a greater number of 
observations in each group in order to reach significance. As our results included 4 – 6 observations 
from at least 2 independent assays, the numbers from siRNA inhibition of PAR2 following sardine and 
king crab trypsin stimulation may reach significance with a greater number of observations. However, 
the lack of significance in trypsin exposed cell is almost certainly due to incompletely knockdown of the 
receptor. To address the non-significant results, the siRNA transfection protocol for PAR2 knockdown 
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in the A549NF-κB-luc cell line will be optimized and the related assays repeated before the manuscript 
is submitted. 
Based on our results and the discussed facts, we are able to make the following conclusion;  
Purified trypsins from different fish species and king crab induce increased secretion of IL-8 from 
human airway epithelial cells, an effect that is mediated by activation of PAR2 following salmon trypsin 
stimulation, and at least partly by activation of PAR2 following sardine and king crab trypsin 
stimulation. 
 
Generation of NF-κB via activation of PAR2 
 
The transcriptional regulation of IL-8 expression in airway epithelial cells is complex and involves the 
transcription factors nuclear-factor kappa-B (NF-κB), NF-IL6, and activating protein (AP)-1 301, 329, 330. 
Binding of the NF-κB element is required for activation in all cell types studied, while the AP-1 and NF-
IL6 sites are not essential for induction but are required for maximal IL-8 gene expression 186-189. PAR2 
is shown to activate NF-κB as well as AP-1 and NF-IL6 in different cell types, including human alveolar 
epithelial cells (A549), emphasizing the importance of PAR2 in inflammation 
148, 178, 214, 331, 332. Both 
trypsin and PAR2 agonist peptide is shown to activate NF-κB 
148, 178, 214, 331, 332, although few works 
have established a firm correlation between trypsin-induced PAR2 activation and NF-κB binding in 
airway epithelial cells. This knowledge motivated us to examine whether purified salmon trypsin, by 
acting as a PAR2 agonist, could activate NF-κB as reported for other serine proteases 
178, 214, 331-335.  
 
In paper II we established a firm correlation between PAR2 activation by salmon trypsin and 
generation of NF-κB by the use of transiently transfected PAR2+ HeLa cells, a cell type that is known 
to lack endogenous PAR2 expression 
1, 97, 319. Purified salmon trypsin as well as PAR2 agonist peptide 
was able to activate NF-κB in PAR2 positive cells, while no response was detected in PAR2 negative 
cells. In paper IV we utilized an A549 cell line stably transfected with a NF-κB-luc element giving us 
the chance to measure activated NF-κB directly without having to transiently transfect the cells prior to 
each assay. We show that both sardine and king crab trypsins are capable of activating NF-κB, an 
effect that seems to be at least partly PAR2 mediated, as knockdown of the receptor using siRNA 
attenuates the NF-κB response. However, the remaining NF-κB levels in PAR2 knockdown cells may 
be due to incomplete delivery of siRNA to the A549NF-κB-luc strain compared to the wild type A549 or 
activation of other receptors and pathways as already discussed for the IL-8 secretion. 
According to the literature, NF-κB is reported to be essential for induction of IL-8 gene expression in 
several cell types/lines. We wished to explore whether this applied to the increased amounts of IL-8 
secreted from A549 cells following sardine and king crab trypsins as well. By the use of an NF-κB 
inhibitor we confirm in paper IV that NF-κB is essential for IL-8 production from A549 cells following 
stimulation with PAR2 agonist peptide and both sardine and king crab trypsins as the IL-8 secretion in 
inhibitor treated cells was completely abolished.  
In conclusion, salmon trypsin induces DNA-binding of the NF-κB transcription factor via activation of 
PAR2 in transfected cells. Trypsins from sardine and king crab induce DNA-binding of the NF-κB 
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transcription factor in human airway epithelial cells, an effect at least partly mediated by activation of 
PAR2. The generation of NF-κB is essential for the increased secretion of IL-8 following stimulation 
with salmon, sardine, and king crab trypsins. 
 
The activation of NF-κB by salmon, sardine, and king crab trypsins is dose-dependent rising up to a 
maximum level that plateaus at enzyme concentrations that detach the cells leaving them in 
suspension during the assay. All the trypsins tested seem to behave similar in capacity of activating 
NF-κB, but with regards to king crab trypsin we observed high levels of NF-κB at enzyme 
concentrations that yielded no detectable secretion of IL-8. For purified sardine the dose-response 
curve for IL-8 followed the generated levels of NF-κB, while for the purified king crab trypsin the NF-κB 
response in the higher enzyme concentrations generated strong levels of NF-κB that failed to translate 
into simultaneous IL-8 secretion. In fact, the IL-8 levels are reduced with 88 – 91% compared to the 
background levels in these tree high enzyme concentrations of king crab trypsin (0,4 – 1 – 2 mU). The 
fact that the concentration-effect curves for NF-κB follows the secreted amounts of IL-8 for the piscine 
trypsins, but not for the king crab trypsin puzzles us as the effects all seems to be mediated by PAR2.   
 
Some proteases are shown to cleave PARs at several sites, including activation and disabling sites, 
and the net result depends on the efficiency of cleavage at different locations 73, 122. Differential 
cleavage is shown to be concentration-dependent with regards to tryptase and inactivation seems to 
occur at 100 nM, while activation is detected already at 1 nM of tryptase. The response produced by 
this dual ability to activate/inactivate PARs will depend on the concentration of agonist in the actual 
tissue. Theoretically, the king crab trypsin could be able to cleave PAR2 at activation and disabling 
sites, and the net result of activation/inactivation may depend upon the concentration of enzyme. 
However, an inactivation of the receptor only explains the lack of IL-8 and not the increased amounts 
of NF-κB, presuming that both these observed effects are mediated by PAR2 activation.  
To investigate the ability of a given protease to cleave the N-terminal end of PAR2, synthetic peptides 
corresponding to this segment may be used to determine the peptide fragmentation created by 
protease cleavage. The cleavage products can be examined by mass spectrometry to identify the sites 
of cleavage and by this give information whether the protease in question is capable of activating 
and/or inactivating PAR2. However, although it has been demonstrated that N-terminal peptides of rat 
and human PAR2 are rapidly cleaved by trypsin at multiple potential cleavage sites that would both 
activate and disarm the receptor 152 (Hollenberg MD, personal communication), rat PAR2 expressed in 
intact cells displays selective tryptic cleavage only at the activation site without cleavage downstreams 
336. To assess activation/disarming of cell expressed human PAR2, a Canadian research group have 
established a receptor desensitization assay 327. By the consecutive application of trypsin, agonist 
peptide and/or the protease to be evaluated in varying orders, they assess if the receptor is activated 
or disarmed by the ability to cause intracellular calcium-signalling. Currently, cleavage data from 
synthetic peptides and activation data from the cell based receptor desensitization assay are 
generated for salmon, sardine, and king crab trypsins by our collaborators in Canada, Dr. Morley 
Hollenberg’s group. We are eagerly awaiting their final results but preliminary studies indicate that 
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salmon, sardine and king crab trypsin are all capable of both activating and disarming human PAR2 in 
the cell based receptor assay in addition to cleavage of synthetic peptides at activation and 
inactivation sites (Hollenberg MD – personal communication).  
 
In theory, a scenario where the PAR2 generated signal translating into NF-κB activation and IL-8 
secretion are shut off due to receptor inactivation arising at this particular enzyme concentration of 
king crab trypsin, while activation of an unknown receptor generating the observed amounts of NF-κB 
due to a different signaling pathway where NF-κB results in transcription of different target genes 
besides IL-8, might be possible. NF-κB is a transcription factor known to regulate the expression of 
over 200 immune, growth, and inflammation genes 313 and are activated by a large number of 
receptors and pathways 314, 337. 
Normally, IL-8 is barely secreted from non-induced cells, but increased production and secretion is 
rapidly induced by a wide range of inflammatory stimuli and cellular stress 186. It is to be expected that 
the background level of IL-8 secreted in our assays is due to activation of different cellular receptors 
and intracellular signaling pathways depending on subtle fluctuations in the extra cellular environment 
during handling of cells grown in vitro, although we strive to standardize their conditions 303, 338, 339. 
However, if this basal level theoretically could be due to PAR2 involvement, an inactivation of the 
receptor might explain the reduced amounts of IL-8 compared to the background level observed in the 
higher enzyme concentrations (0,4 – 1 – 2 mU) of king crab trypsin. 
 
There may also be a possibility that king crab trypsin cleaves the N-terminal end of PAR2 differently 
compared to the fish trypsins and by this activating other PAR2 coupled signalling pathways yielding 
different end products besides the secretion of IL-8. For many G protein-coupled receptors like those 
for angiotensin II, dopamine, serotonin, and adrenergic ligands, differential signaling depending on the 
activating ligand are now accepted 90-93. This phenomenon is termed “agonist-biased signaling” or 
“functional selectivity”. Recent data also indicate that the proteolytically-revealed tethered ligand 
sequence(s) and the mode of its presentation to the receptor (tethered vs. soluble) can confer biased 
signaling by PAR2 
89. In the study by Ramachandran and co-workers activation of PAR2 is measured 
by its ability to elevate intracellular Ca2+ and/or activate ERK/p42/44 MAP kinase in stably ratPAR2-
transfected KNRK cells, a cell type shown to express very low levels of functional PAR2 
97. The group 
shows that even though the ability of the tethered ligand to stimulate an elevation in intracellular Ca2+ 
is lost when the two first amino acids of the ligand (S37L38) is mutated to alanines or switched in order 
(L37S38), the activation of MAP kinase is retained. Furthermore, the synthetic PAR2 activating peptide 
SLAAA-NH2 activates MAP kinase, but is not capable of stimulating an elevation in intracellular Ca
2+. 
This in contrast to the scenario where the same sequence is presented to the receptor as a tethered 
ligand and in this form activates both MAP kinase and calcium signalling.  
Along with the first two amino acids of the trypsin-revealed tethered ligand (S37L38), additional residues 
are considered important for receptor activation. Receptor chimera studies of the human-Xenopus 
PAR1 receptor suggest a possible interaction between the positive Arg
5 in SFLLRN and the negative 
Glu260 in the second extracellular loop of the PAR1 
85, 86. These amino acids are also conserved in 
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PAR2. Thus, an Arg
5-Glu260 interaction might also operate in recognition of the PAR2 agonist peptide 
SLIGRL by PAR2. Arg
5 in the PAR2 agonist peptide SLIGRL corresponds to the positive arginine at 
position 41 of the revealed tethered ligand. When this residue is changed to either a neutral alanine or 
a negative glutamatic acid (changing SLIGRL to SLIGAL or SLIGEL) these sequences presented to 
the receptor in form of soluble peptides has a marked reduction in the ability to cause intracellular Ca2+ 
signalling (potency reduced by at least 32-fold for SLIGAL and 130-fold for SLIGEL). Interestingly, 
when Arg41 is changed in the tethered ligand the mutated receptors are able to give equivalent 
responses in intracellular calcium signalling showing that the trypsin-revealed PAR2 tethered ligand 
sequence interacts differently for receptor activation that does the same peptide sequence as a free 
peptide 77. Although these results diverge with respect to the response produced by mutated PAR2 
agonist peptides versus mutated tethered ligand, changes in electrostatic potential seems to be an 
important aspect in the binding of agonist to PAR2 receptor.  
 
During purification of several fish trypsins and trypsin from the king crab by fast protein liquid 
chromatography (FPLC), we observed that king crab trypsin bound stronger to the anionic column 
compared to the other fish trypsins. Knowing that molecular size, conformation and electrostatic 
potential will influence on a molecule’s ability to bind and interact with signalling partners we decided 
to explore this divergence further.  
 
In paper III we show by molecular modelling that the surface of king crab trypsin display a large area 
with strong negative electrostatic potential compared to the smaller negative areas of bovine and 
salmon trypsins. In addition these latter trypsins also display areas with strong positive electrostatic 
potentials, a feature lacking in king crab trypsin. Because of the lack of a full amino acid sequence of 
the sardine trypsin molecule we were not able to do any modelling of and comparison with sardine 
trypsin. The modelling of bovine, salmon, and king crab trypsins suggest that at least 3 divergent 
positions are located near the substrate binding pocket and might affect the binding of substrate to 
PAR2.  
1) The positive Arg244 in the king crab trypsin corresponds to the negative Glu221 in salmon 
trypsin and the neutral Gln199 in bovine trypsin. 
2) The neutral Tyr247 in king crab trypsin corresponds to the neutral Asn224 in salmon trypsin and 
to the positive Lys202 in bovine trypsin. 
3) The negative Asp196 in king crab trypsin corresponds to the neutral Met175 in salmon trypsin 
and the neutral Gln155 in bovine trypsin. 
 
It is possible that the positive Arg36 (and/or positive Lys34) of PAR2 may interact differently with the 
binding pocket in the three trypsins. Because of differences in the electrostatic potential it is possible 
that PAR2 might bind weaker to king crab trypsin than to other trypsins due to repulsive interactions 
between the positive Lys34/ Arg36 in PAR2 and the positively charged Arg
244 in king crab trypsin. This 
residue corresponds to a negative amino acid (Glu221) in salmon trypsin and a neutral amino acid 
(Gln199) in bovine trypsin. Recently, Zhang and co-workers (2009) have documented that electrostatic 
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interactions presumably play an important role in alignment of the PAR2 N-terminal end with its 
activating protease domain 340. By the use of molecular simulations they show that positive amino 
acids in the proximity of the cleavage site of PAR2 are located close to negatively charges residues on 
the binding pocket surface of the activating protease (factor VIIa [FVIIa]), whereas negatively charged 
residues from the N-terminal domain are close to positively charged FVIIa residues. These results 
indicate that electrostatic interactions in specific regions may guide substrate orientation.  
Additionally, this report indicates that because of the large discrepancy in distance between the active 
site of FVIIa and the cell membrane compared to the cleavage site of PAR2 and the cell membrane, 
the FVIIa molecule must be tilted towards the cells membrane in order to bind and cleave the PAR2 
extra cellular tail. This is a process that may need additional protein interactions. The king crab trypsin 
is shown to be a slightly bigger molecule (28 – 29 kDa) compared to salmon and sardine trypsins (23,7 
– 25 kDa) 341-345. Whether this slight increase in size would affect the ability of king crab trypsin to 
interact with the N-terminal domain of PAR2 needs further investigation to be answered.  
 
Although a weakened receptor interaction due to change in electrostatic potential might explain the 
differences between king crab and salmon trypsin with respect to NF-κB activation and IL-8 secretion, 
we would by this expect king crab trypsin to be a less potent PAR2 agonist compared to salmon 
trypsin. According to pharmacological principles, an agonist with inferior affinity for a receptor require a 
higher concentration at the site of binding to produce a similar response compared to an agonist 
possessing superior affinity. Meaning that in order for the king crab trypsin to produce similar effect, 
here measured by the secretion of IL-8, comparable to sardine and salmon trypsins we would have to 
stimulate the cells with higher enzyme concentrations. Opposing to this we observed that king crab 
trypsin was able to induce secretion of IL-8 in a much lower concentration range than salmon and 
sardine trypsin as maximum response was seen with 0,02 mU of enzyme for king crab trypsin 
compared to 0,2 mU of enzyme for the sardine trypsin and 1 mU of enzyme for the salmon trypsin. 
However, the maximal level of IL-8 compared to untreated cells were lower in the king crab trypsin 
stimulations with a 9-fold increase, as opposed to a 18-fold increase in the sardine trypsin-stimulated 
cells and a 20-fold increase for the salmon trypsin. Regarding the ability to activate NF-κB both king 
crab trypsin and sardine trypsin produces maximum NF-κB response at the same concentration (0,4 
mU of enzyme) but maximal level of NF-κB in king crab trypsin-stimulated cells yielded a 13-fold 
increase compared to untreated cells as opposed to a 9-fold increase for sardine trypsin (activation of 
NF-κB were not measured in the A549 cell type for salmon trypsin). 
In brief summary, king crab trypsin seems to be more potent with regards to eliciting an IL-8 response, 
but less potent compared to the fish trypsins regarding the ability to produce maximal IL-8 secretion. 
Regarding the ability to generate DNA-binding of NF-κB, king crab trypsin seems to be more potent 
than sardine trypsin both with regards to induction of a response and the strength of the response. If 
these observed differences could be a result of the ability to activate or inactivate PAR2 at different 
enzyme concentrations, due to agonist biased signalling yielding a differentiated response by 
activation of separate signalling pathways based upon the concentration of enzyme or originate from 
an inferior binding capacity due to electrostatic forces is presently unknown. 
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Knowing that binding of the AP-1 and NF-IL6 elements in addition to NF-κB are required for maximal 
IL-8 gene expression 186-189, it is tempting to speculate in the fact that these transcription factors may 
be regulated differently by the king crab trypsin compared to the fish trypsins. The measurements of 
NF-κB in this study were chosen in order to achieve a stronger connection to signaling pathways 
resulting in airway inflammation. Time limitations did not allow us to explore the relationship between 
the trypsins and the AP-1 and NF-IL6 binding sites, although this would be an interesting topic for 
prospective studies. 
In conclusion, the generated NF-κB leads to increased secretion of IL-8 for all trypsins apart from the 
highest enzyme concentrations of king crab trypsin. The signaling events that lead to high levels of 
activated NF-κB without subsequent secretion of IL-8 in the elevated concentrations of king crab 
trypsin are presently unknown. However, based on the NF-κB readings from the siRNA inhibition 
assays, PAR2 seems to be involved to some extent. Additionally, the mechanisms responsible for 
what, despite high NF-κB levels, seems to be an inhibition of the basal secretion of IL-8 in the highest 
enzyme concentrations of king crab trypsin needs further investigation to be explained. 
 
Activation of MAP kinases as part of the PAR2 signal transduction 
cascades leading to increased IL-8 secretion 
 
Virtually all stressful and pro-inflammatory stimuli known to induce IL-8 production activate a number 
of protein kinases. Hoffmann and co-workers (2002) have determined that maximal IL-8 amounts are 
generated by a combination of three different mechanisms 186: 
1) De-repression of the gene promoter.  
2) Transcriptional activation of the gene by transcription factors and c-Jun-N-terminal protein 
kinase (JNK) pathways. 
3) Stabilization of the mRNA by the p38 mitogen-activated pathway. 
In addition to NF-κB, activation of the MAP kinases ERK 1/2, JNK, and p38 is shown to be required for 
maximal IL-8 expression in TNFα-stimulated human airway epithelial cells 346. The involvement of 
MAPKs in PAR2-mediated IL-8 synthesis in airway cells is recently investigated and is found to be 
dependent on activation of ERK1/2 and JNK, while the involvement of p38 is more uncertain. ERK1/2 
and JNK, but not p38 are reported to be involved in the PAR2 agonist peptide induced IL-8 secretion 
from A549 cells in some studies 179, 181, while others report an involvement of all three kinases 178. 
 
In paper IV we explored the contribution of MEK/ERK and p38 to the secretion of IL-8 following 
stimulation of A549-NF-κB-luc+ cells with purified sardine and king crab trypsins by the use of specific 
inhibitors. ERK 1/2 activation has been demonstrated to be required for IL-8 mRNA and protein 
expression in airway epithelial cells (A549) 347, and PAR2 has been shown to activate ERK 1/2 in 
human bronchial epithelial cells (16HBE14o) 147 and the A549 cell line 179, 181. In line with previous 
results we observed a pronounced reduction in the secreted levels of IL-8 when MEK/ERK was 
inhibited. The reduction was close to similar in PAR2 agonist peptide (SLIGRL-NH2), sardine trypsin, 
and king crab trypsin stimulated cells with 86, 84, and 65% respectively. The influence of inhibitors on 
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the NF-κB generation was also investigated to determine whether activation of the MAP kinases is 
essential for NF-κB activation or not. The NF-κB levels remained almost unchanged in the inhibitor 
treated PAR2 agonist peptide and sardine trypsin stimulated cells, indicating that the contribution of 
MEK/ERK to the secretion of IL-8 is a NF-κB-independent process. However, in the king crab trypsin 
stimulated cells the NF-κB levels increased with 16 – 25% in inhibitor treated cells. Although not 
significant, the result could imply that king crab trypsin activates distinct signaling pathways that 
through MEK/ERK involvement contribute to inhibition of the generation, nuclear translocation and/or 
DNA-binding of activated NF-κB.  
 
P38 is primarily believed to regulate the IL-8 protein expression at a post-transcriptional level 
stabilizing the IL-8 mRNA transcript 186, 346. On the other hand, the p38 pathway is also shown to 
contribute to transcriptional activation by modulating the transactivation capacity of the NF-κB p65 
subunit in TNF-activated murine fibrosarcoma cells 348. P38 activity is also shown to be required to 
enhance the accessibility of the cryptic NF-κB binding sites contained in H3 phosphorylated 
promoters, indicating that p38-dependent H3 phosphorylation may mark promoters for increased NF-
κB recruitment 349. In primary human dendritic cells this p38-dependent phosphorylation and 
phosphoacetylation of histone H3 is shown to be induced by inflammatory stimuli, selectively occurring 
on the promoters of cytokine and chemokine genes. The involvement of p38 in PAR2 mediated IL-8 
secretion from human airway epithelial cells is presently uncertain. The use of a p38 inhibitor 
(SB203580) at 10 uM failed to affect the secretion of IL-8 in the study conducted by Ostrowska and 
Reiser (2008) 179, and Moriyuki and co-workers (2008) 181 observed no effect using the same inhibitor 
at 1 uM. Adam and co-workers (2006) 178 who reports of p38 involvement in the PAR2 mediated 
secretion of IL-8 have also included inhibitor studies demonstrating inhibition of p38 using SB203580 
at 25 uM.  
We observed a pronounced reduction in the secreted levels of IL-8 following PAR2 peptide (52%), 
sardine (35 – 45%), and king crab trypsin (40%) stimulation in A549 cells treated with p38 inhibitor 
(SB202190 at 10 uM). In contrast with former information we observed a reduced level of NF-κB 
following p38 inhibition both in peptide and trypsin stimulated cells (46% reduction in PAR2 agonist 
peptide, 44 – 49% reduction in sardine trypsin, and 53% in king crab trypsin). This indicates that p38 in 
addition to regulating the IL-8 protein expression at a post-transcriptional level may influence upon 
activation of NF-κB, nuclear translocation or/and DNA binding of activated NF-κB in A549 cells.  
Care should be taken when interpreting data obtained with inhibition of p38 MAPK by the 
pyridylimidazole analogues (SB203580, SB202190) and reflections should be made regarding the 
concentrations applied. These inhibitors are highly specific, but a few other kinases (Raf and 
lymphocyte kinase) are inhibited by SB203580, albeit less potently than p38 350-352. Hall-Jackson and 
co-workers (1999b) have shown that SB203580 inhibits c-Raf with an IC50 of 2 µM in vitro, however 
SB203580 at 10 – 25 µM does not suppress the classical MAP kinase cascade in mammalian cells 
(rat PC12 cells 353, human KB cells 353, 354, mouse C3H 10T1/2 cells 355, mouse Swiss 3T3 cells, or rat 
L6 myotubes 352). On the contrary, SB203580 (10 µM) induces a remarkable activation of c-Raf that 
may counterbalance its inhibition 352. These studies do not include SB202190, the inhibitor of our 
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choice, but SB203580 and SB202190 are structurally alike and similar effects may be expected. 
Activation of the protein kinase c-Raf triggers the sequential activation of MAPK kinase-1 (MEK1) and 
the MAP kinases ERK1/2. Inhibition of Raf would result in diminished activation of MEK/ERK and in 
our case a reduced secretion of IL-8, as activation of MEK/ERK previously are shown to be important 
for the observed IL-8 secretion in trypsin and agonist peptide stimulated A549 cells. Based on this 
information, it may be somewhat substantial to claim that the reduced amounts of secreted IL-8 in p38 
inhibitor treated A549 cells must be due to inhibition of p38, however it is most likely.  
With regards to the reduced level of NF-kB in p38-inhibitor treated cells, it is more unlikely that this 
could be due to an undesired inhibition of Raf and subsequent loss of MEK/ERK activation as we have 
shown that inhibition of this pathway does not influence upon the activation of NF-kB.  
In order to confirm if the observed reduction in secreted IL-8 in fact is due to inhibition of p38 following 
the use of p38 inhibitors, blots indicating the presence of active (phosphorylated) and inactive 
(unphosphorylated) forms of p38 and ERK1/2 could be performed. Validation of the observed results 
could also be done by over-expressing a drug-resistant mutant of the protein kinase. If the observed 
effects do not disappear when introducing this drug-resistant mutant, they may be due to inhibition of 
other targets than the indicated kinase. Due to time limitations we were not able to perform these 
types of experiments for verification, although it would have been desirable. None of the addressed 
studies employing SB203580 for inhibition of p38 in the A549 cell type have confirmed their observed 
effects with additional studies 178, 179, 181. Based on searches in available medical databases (PubMed, 
MedLine, EmBase etc.) we have not been able to identify any works using the p38 inhibitor of our 
choice (SB202190) in studying the contribution of p38 to increased secretion of IL-8 following PAR2 
activation.     
In conclusion, increased secretion of IL-8 from human airway epithelial cells following stimulation with 
sardine and king crab trypsins are dependent on activation of the MAP kinases ERK 1/2 and p38, in 
addition to generation of the transcription factor NF-κB. The contribution of the ERK 1/2 pathway to the 
increased secretion of IL-8 is a NF-κB-independent process, while the contribution of the p38 pathway 
seems to influence upon activation, nuclear translocation and/or DNA binding of activated NF-κB in 
addition to a probable regulation of the IL-8 protein expression at a post-transcriptional level. Besides 
the slight, non-significant, increase in NF-κB following MEK/ERK inhibition in king crab trypsin 
stimulated cells, no obvious differences were found between the sardine and king crab trypsins that 
can explain the lack of IL-8 secretion despite high NF-κB levels in the elevated enzyme concentrations 




This work demonstrates that purified trypsins from salmon, sardine, and king crab induce increased 
secretion of IL-8 from human airway epithelial cells. The secretion is mediated by the activation of 
PAR2 for salmon trypsin and most probable also for sardine and king crab trypsin although ineffective 
PAR2 knockdown in A549NF-κB-luc cells prevents strong conclusions for the latter. As the siRNA 
protocol is currently optimized for this A549 cell strain, the PAR2 knockdown assays will be repeated 
before paper IV is submitted. All trypsins activate the transcription factor NF-κB, a process that is 
mediated by the activation of PAR2 for salmon trypsin and most likely for sardine and king crab 
trypsins as well.  
Increased IL-8 secretion following sardine and king crab trypsin stimulation is dependent on the 
transcription factor NF-κB for induction and the MAP kinases ERK 1/2 and p38 for maximal 
expression. The involvement of the ERK 1/2 pathway to the increased secretion of IL-8 is a NF-κB-
independent process, at least regarding the sardine trypsin. A moderate, but non-significant, rise in 
NF-κB levels following MEK/ERK inhibition during king crab trypsin stimulation could imply that king 
crab trypsin activates signalling pathways that through MEK/ERK involvement might inhibit the 
activation of NF-κB, but these results should only be treated as indicative. In contrast to previous 
research, we found the contribution of the p38 pathway to the increased IL-8 secretion to be partly 
connected to NF-κB activation, in addition to a probable regulation of the IL-8 protein expression at a 
post-transcriptional level as reported by others. 
 
Different variants of trypsin are shown to cleave and activate PAR2, but little research contains 
comparison of the downstream signalling response produced by different trypsins in human airway 
epithelial cells. At first glance the trypsins from fish and king crab seem to behave similarly in our cell-
based assays. However, our research has revealed several areas where king crab trypsin differs from 
the fish trypsins: 
 
1) The dose-response relationship for IL-8 in human airway epithelial cells shows that king crab 
trypsin is more potent in initiating secretion of IL-8 from human airway epithelial cells 
compared to salmon and sardine trypsin. 
2) King crab trypsin yields a lower maximal level of secreted IL-8, 
3) but a higher maximal level of activated NF-κB compared to the fish trypsins. 
4) The generated NF-κB does not translate into subsequent IL-8 secretion in the highest enzyme 
concentrations as opposed to fish trypsin generated NF-κB. 
5) King crab trypsin seems to inhibit the basal levels of IL-8 secretion in the highest enzyme 
concentrations. 
6) King crab trypsin seems to activate signalling pathways that by the involvement of MEK/ERK 
exhibit negative regulation of NF-κB. 
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If these observed differences in the king crab trypsin are due to structural relationships in the king crab 
trypsin molecule influencing upon alignment of the PAR2 N-terminal end with the protease and by this 
activating distinct signalling pathways, due to a concentration-dependent receptor activation-
inactivation relationship, or if they are due to activation and involvement of other receptors are 
presently unknown.  
A possible agonist biased signalling based on subtle differences in what has been expected to be 
similar agonists may answer many of the diverging results found following PAR2 activation in different 
cell lines and tissues. Further investigation of this topic can contribute to a better understanding of 







Our results from cell based assays indicate that seafood trypsins have the potential to initiate 
inflammatory signalling in airway epithelial cells. In order to determine if exposure to trypsin could be 
the cause of observed airway symptoms in seafood industry workers, more extensive studies must be 
conducted. Methods for quantification of total protease activity in inhaled air samples at the workplace 
must be optimized, and studies addressing the effects of combined exposure should be executed as 
aerosols in the working environment are shown to contain additional components (molds, endotoxins, 
allergens) that may affect induction of airway inflammatory processes.  
 
In order to speculate if inhalation of trypsin from fish or crustaceans may be a causative agent leading 
to airway inflammation and development of airway symptoms we need to consider the following; 
- Is the amount of proteases found in the working environment sufficient to produce effects 
comparable to the observed results in the cell based assays? 
- How and to what extent do the proteases found in environmental samples from the 
workplace come in contact with the airway tissue? 
 
Measurement of enzymatic activity in water samples taken from work stations in the salmon industry 
show a protease activity that is well above the concentrations yielding maximal IL-8 secretion in the 
cell based assays (see fig 4). Samples collected in the king crab industry show somewhat lower 
trypsin-like activity compared to the environmental samples from the salmon industry. However, the 
concentration of king crab trypsin yielding maximal effect in the cell based assays is considerably 
lower than what we found for the salmon trypsin, leaving the levels measured in the environmental 
samples still 2 orders of magnitude above the maximal effective concentration in the cell based 
assays. 
 
In order for the serine proteases detected in the environmental samples to induce airway symptoms 
they would have to come in contact with the airway tissue, an event that takes place if the proteases 
are inhaled. Many of the workstations in the salmon and king crab industry involve mechanical 
processing of biological material and the use of water or airjets creates small particles/ droplets 
harbouring biological material (bioaerosols) that may be inhaled. Measurements taken from the 
breathing zone of workers in the salmon industry show serine protease activity, measured by the 
running of gel zymography of filter extracts (Bang B. – unpublished results). The protease activity of 
these filter extracts are too low to be measured by the serine protease assay described above, and 
optimization of methods to be used for quantification of proteases in air samples must be conducted 
before we are able to assess the amount of inhaled proteases. It has to be mentioned that the amount 
of trypsin applied in the cell based assays would be equally difficult to measure as the concentration of 
the stimulation solutions are based upon serial dilutions of the purified enzyme originally measured by 












Based on the results we have from environmental samples collected in the fish industry, it is not 
unlikely that fish and crab industry workers may inhale proteases in amounts that could affect the 
airway epithelial cells. Purified trypsins from fish and king crab are shown to induce production and 
secretion of inflammatory mediators (NF-kB, IL-8) in our cell based assays, but whether inhalation of 
trypsins is the sole cause of the observed symptoms or if they contribute to a situation with combined 
exposure (proteases, molds, endotoxin, allergens, cold environment) creating potentiating or related 
effects needs further investigation to be answered. 
Figure 4 
The trypsin-like activity in water sampled at workplaces in the salmon and king crab industry was measured in a serine 
protease assay where the hydrolyzation of a chromogenic substrate (DL-BAPNA) was determined just as described 
for purified trypsins 1 and expressed as milliunits (mU)/ml (Bang B. – unpublished results). Max effect for king crab 





The signal transduction involved in airway inflammation caused by serine proteases encompasses 
numerous mediators most probably originating from a complex interplay between different receptors. 
Prospective research should seek to identify the mutual roles of the components implicated and 
elucidate the contribution made from PARs to the inflammation response. The results presented in this 
work strongly indicate that trypsins originating from fish and king crab have the potency of initiating or 
contributing to inflammatory reactions in human airway epithelial cells through the activation of PAR2. 
Although we have chosen to focus on PAR2 and its possible role in mediating inflammatory signals, 
other PAR-family members may also be involved in a tissue response toward serine proteases. 
Preliminary results from our collaborators in Canada, Dr. Morley Hollenberg and co-workers, show that 
salmon, sardine, and king crab trypsins are all able to cleave and unmask the tethered ligand 
sequence of short synthetic peptides corresponding to the N-terminal end of PAR1 and PAR4 in 
addition to PAR2. Additionally, salmon trypsin is shown to activate calcium signalling via human PARs 
1 and 2 in human embryonic kidney cells (HEK) and both salmon, sardine, and king crab trypsins are 
shown to aggregate rat platelets via rat PAR4 (Hollenberg M.D. – personal communication). Trypsin is 
also previously shown to activate PAR1 in addition to PAR2, although in higher enzyme concentrations 
than the ones used in our cell based assays 63, 327. 
PAR-signalling in intact tissue is most likely a multifaceted interplay between different PAR-family 
members. Knowing that intermolecular receptor activation between different PAR family members, in 
addition to the most common picture described with intramolecular receptor activation by the 
receptors own tethered ligand, is a probable scenario, the contribution of other PAR family members to 
the inflammatory signal initiated by PAR activation following trypsin stimulation in human airway 
epithelial cells would be highly interesting to investigate. Airway epithelial cells are shown to express 
both PAR1 and PAR2 
73, 109 and their expression relative to each other in the A549 cell line could be 
investigated by the use of real time PCR and immunohistochemistry. Furthermore, knockdown of the 
receptors, both individually and combined, by the use of siRNA could be used to detect their relative 
contribution to the release of inflammatory mediators. 
 
Agonist biased signalling by PAR2 has recently received attention and might be one explanation for 
the observed discrepancy in effects following receptor activation in different cell lines and tissues. 
Knowing that the king crab trypsin molecule displays a different net molecular charge and harbours 
substituted amino acid residues at seemingly important interaction points close to the substrate 
binding pocket, conducting more extensive molecular modelling studies would be of interest in order to 
explore the impact this would have on receptor binding, cleavage and activation. The results 
presented by us indicate that king crab trypsin may behave differently in activating PAR2 compared to 
trypsins from fish, as shown by the high levels of activated NF-κB, at least partly mediated by PAR2, 
which fails to translate into subsequent IL-8 secretion in the higher enzyme concentrations. Studies 
using PAR2 receptor mutants as well as trypsin mutants would be effective in generating information 
about important residues for receptor cleavage and activation. This might be used in the attempt of 
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identifying possible interaction points where the enzyme-receptor binding differ between king crab and 
fish trypsins, perhaps giving rise to biased signalling. In order to understand the complexity of trypsin-
induced PAR signalling it is important to determine the extent of biased signalling that might arise 
following receptor activation with what previously were considered to be agonists with similar effects. 
Knowing that the transcription factors AP-1 and NF-IL-6 are shown to be necessary for maximal 
expression of IL-8, their relative contribution to the IL-8 secretion following stimulation with king crab 
and fish trypsins would be interesting to determine. One hypothesis might be that biased signalling 
following PAR2 activation by king crab trypsin leads to differential activation of the transcription factors 
NF-κB, AP-1, and NF-IL-6 according to enzyme concentration. 
 
Future projects should also aim to link our previous results closer to the real situation by taking into 
consideration the mixed nature of biological exposures in work environments. The concomitant 
exposure of enzymes, allergens, micro organisms, and microbial components will cause activation of 
several signalling pathways at the same time. The activation of one signal pathway may thus 
exacerbate or attenuate the signal from another pathway. Microbial derived endotoxins, 
peptidoglycans, and β(1-3)-glucan are all signalling though surface receptors coupled to intracellular 
pathways with a number of possible cross-communication links with the PAR-mediated signals. LPS is 
shown to up regulate the expression of PAR2 in human airway epithelial cells and combined 
stimulation with LPS and PAR2 agonist peptide have a potentiating effect on the stimulation of the IL-8 
synthesis 161. Samples taken from the breathing zone of workers in the seafood industry shows that 
inhalation of aerosols containing endotoxins and micro organisms in addition to compounds with 
different enzymatic activity is possible 2. Furthermore, the proallergic cytokine, thymic stromal 
lymphopoietin (TSLP), secreted by airway epithelial cells represent a cross-communication link 
between the innate inflammatory and the allergic (Th-2) cytokine cascades 356. Trypsin is shown to 
induce production of TSLP from airway epithelial cells through PAR2 
270. 
Knowing that concomitant stimulation with different agents can initiate an intricate interplay in receptor 
expression and activation, combinatorial effects of different exposures in airway cells should be 
investigated in order to approach the possible pathogenesis of the observed airway effects in fish 
industry workers. Considered that PAR2 activation is shown to involve both innate and acquired 
immune responses, studies with the aim of identifying the mutual contribution of these responses to 
the effects observed following PAR2 activation in vitro and in vivo will be important for an improved 




A549 cells  Human pulmonary epithelial cell line 
AP-1   Activator protein 1 
BAL   Bronchoalveolar lavage 
BEAS-2B cells  Human bronchial epithelial cell line 
C3H 10T1/2 cells Mouse embryo-derived cell line 
cAMP   Cyclic adenosine monophosphate 
c-Cbl   E3 ligase 
CD11/CD18  Integrins, leukocyte adhesion molecules 
CG   Cathepsin G 
c-Jun   Component of the AP-1 transcription factor complex 
COPD   Chronic obstructive pulmonary disease 
COS-7 cells  Simian kidney cell line 
COX-2   Cyclooxygenase-2 
c-Raf   MAP kinase kinase kinase (MAP3K) 
CREB    cAMP responsive element binding protein 
DAG   Diacylglycerol 
Der P3/Der P9 Serine proteases from Dermatophagoides pteronyssinus and D.  farinae (dust mite) 
DL-BAPNA  Na-Benzoyl-D,L-arginine 4-nitroanilide hydrochloride 
DUB Deubiquitinating protease 
EBC-1 cells Human pulmonary squamous cell carcinoma cell line 
EC50   Median effective concentration (required to induce a 50% effect) 
ECL   Extra cellular loop of PAR 
EGF-R   Epidermal growth factor receptor 
EPa  Elastolytic metalloprotease from Pseudomoas aeruginosa (LasB or pseudolysin) 
ERK   Extracellular-signal regulated kinase 
FAK   Focal adhesion kinase 
FVIIa   Coagulation factor IIa 
FXa   Coagulation factor Xa 
GDP   Guanosine diphosphate 
GM-CSF  Granulocyte-macrophage colony-stimulating factor 
GPCR   G protein-coupled receptor 
GRK   G protein receptor kinases 
GTP   Guanosine triphosphate 
HAT   Human airway trypsin-like protease 
HBE cells  Human bronchial epithelial cell line 
HEK293 cells  Human embryonic kidney cells 
HeLa cells  Human epithelial cervical cancer cell line 
HNEPC   Human nasal epithelial cell line 
Hrs   Hepatocyte growth factor regulated tyrosine kinase substrate   
IC50   Half maximal inhibitory concentration (required to induce a 50% inhibition) 
ICAM-1   Intercellular adhesion molecule 1 
IFN   Interferon 
IgE   Immunoglobulin E 
IκB   Inhibitor of κB 
IKK   IκB kinase 
IL   Interleukin 
IP3   Inositol-1,4,5-trisphosphate 
Jab1   Jun activating binding protein-1 
JNK   C-Jun-N-terminal kinase/stress-activated protein kinase (SAPK), class of  
mitogen-activated protein kinase 
Jun D   Component of the AP-1 transcription factor complex 
KB cells  Human epidermoid carcinoma cell line 
KLKs   Kallikreins 
KNRK cells  Rat kidney fibroblast cell line  
LepA   Large exoprotease with a trypsin-like serine protease motif from Pseudomonas  
aeruginosa 
LPS   Lipopolysaccharide 
MAPK   Mitogen-activated protein kinase 
MCT   Mast cell tryptase 
MEK   MAPK/ERK kinase 
MIP-2   Macrophage inflammatory protein 2 
MMP-9   Matrix metalloprotease 9 
MT-SP1   Membrane-type serine protease 1 
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NE   Neutrophil elastase 
Neu7 cells  Rat primary cortical astrocyte cell line 
NF-IL6   Nuclear factor for interleukin-6 (C/EBP; CCAAT/enhancer binding protein beta) 
NF-κB   Nuclear factor kappa-light-chain-enhancer of activated B cells  
OA   Occupational asthma 
OR   Occupational rhinitis 
P22   Tryptic-like serine protease from rat brain 
P38   Class of mitogen-activated protein kinase 
PAR   Protease activated receptor 
PAR-AP   PAR activating peptide/PAR agonist peptide 
PC-3 cells  Human prostate cancer cell line 
PC-12 cells  Rat adrenal medulla pheochromocytoma cell line 
Pen c 13  Serine protease from Penicillium citrinum 
PGE2   Protaglandin E2 
PI3K   Phosphoinositide 3-kinase 
PKA   Protein kinase A 
PKC   Protein kinase C 
PLA2   Phospholipase A2 
PLCβ   Phospholipase Cβ 
PR3   Proteinase 3 
RgpB   Arginine-specific cysteine protease from Porphyromonas gingivalis 
Rho A   Ras homolog gene family, member A 
RhoGEF  Rho-activating guanine-nucleotide exchange factors 
ROCK   Rho-associated kinase  
SAEC   Small airway epithelial cells 
SiRNA   Small interfering/inhibitory ribonucleic acid 
SW620   Human colon carsinoma cell line 
Swiss 3T3 cells  Mouse embryo-derived fibroblast like cell line 
TF   Tissue factor 
TL   Tethered ligand 
TLR   Toll-like receptor 
TNF   Tumor necrosis factor 
TSLP   Thymic stromal lymphopoietin 
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